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ABSTRACT 
Wei-Lun Hsu 
 
Mechanisms of Binding Diversity in Protein Disorder: Molecular Recognition Features 
Mediating Protein Interaction Networks  
 
Intrinsically disordered proteins are proteins characterized by lack of stable 
tertiary structures under physiological conditions. Evidence shows that disordered 
proteins are not only highly involved in protein interactions, but also have the capability 
to associate with more than one partner. Short disordered protein fragments, called 
“molecular recognition features” (MoRFs), were hypothesized to facilitate the binding 
diversity of highly-connected proteins termed “hubs”. MoRFs often couple folding with 
binding while forming interaction complexes. Two protein disorder mechanisms were 
proposed to facilitate multiple partner binding and enable hub proteins to bind to multiple 
partners: 1. One region of disorder could bind to many different partners (one-to-many 
binding), so the hub protein itself uses disorder for multiple partner binding; and 2. Many 
different regions of disorder could bind to a single partner (many-to-one binding), so the 
hub protein is structured but binds to many disordered partners via interaction with 
disorder. Thousands of MoRF-partner protein complexes were collected from Protein 
Data Bank in this study, including 321 one-to-many binding examples and 514 many-to-
one binding examples. The conformational flexibility of MoRFs was observed at atomic 
resolution to help the MoRFs to adapt themselves to various binding surfaces of partners 
or to enable different MoRFs with non-identical sequences to associate with one specific 
viii 
 
binding pocket. Strikingly, in one-to-many binding, post-translational modification, 
alternative splicing and partner topology were revealed to play key roles for partner 
selection of these fuzzy complexes. On the other hand, three distinct binding profiles 
were identified in the collected many-to-one dataset: similar, intersecting and 
independent. For the similar binding profile, the distinct MoRFs interact with almost 
identical binding sites on the same partner. The MoRFs can also interact with a partially 
the same but partially different binding site, giving the intersecting binding profile. 
Finally, the MoRFs can interact with completely different binding sites, thus giving the 
independent binding profile. In conclusion, we suggest that protein disorder with post-
translational modifications and alternative splicing are all working together to rewire the 
protein interaction networks. 
 
A. Keith Dunker, Ph.D., Committee Chair 
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CHAPTER 1 
Introduction 
 
1.1. Intrinsic Protein Disorder and Protein Functions  
Intrinsically disordered proteins (IDPs) are a group of proteins that lack stable 
tertiary structures either partially or in their entirety. Their structural conformations are 
too dynamic to be described by a single conformation under physiological conditions. 
IDPs still can be identified by more than 40 experimental methods, such as x-ray 
crystallography (missing density), Nuclear magnetic resonance (NMR) (lack of chemical 
dispersion in 1H-15N NOEs), far-UV (170-250nm) circular dichroism (lack of secondary 
structure), protease sensitivity (readily cleaved by proteases), 1-Anilino-8-naphthalene-
sulfonate (ANS) binding (lack of hydrophobic cores) and so on.  Protein disorder has 
been found to exist in nature as disordered tails, linkers, domains, or entirely unfolded as 
collapsed or extended forms (Figure 1) [1]. The existence of IDPs challenge the 
traditional biochemistry view of sequence-structure-function paradigm since these 
proteins still carry out important biological functions without well-defined structures. In 
other words, the structure of a protein may not always define its function or a single 
unique structure cannot describe their function. However, in some cases, these disordered 
regions can adopt specific three dimensional structures after binding to another molecule. 
There are some possible reasons why IDPs lack stable structures. Some researchers 
believe IDPs are unstructured only when lacking a ligand/partner or other factors that 
promote their folding, but others, including our laboratory, believe IDPs’ lack of structure 
is encoded by their amino acid sequences just like structured proteins. 
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Figure 1. Various forms of protein structures: (A) structured domain, (B) disordered 
domain, (C) disordered tails, (D) disordered linker, (E) collapsed disorder and (F) 
extended disorder. Red parts of structures imply disordered regions. The diagram is 
adapted from DisProt Database [1]. 
  
A B 
C D 
E F 
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IDPs are often referred to using alternative names, such as naturally unfolded 
proteins, intrinsically unstructured proteins, flexible/dynamic proteins, conformational 
disorder, extended polypeptide, mobile domains, molten globule, random coils or 
disordered proteins. Genomics and proteomics studies have revealed protein disorder is 
highly abundant in various organisms, such us in humans and viruses. Eukaryotes 
generally have higher intrinsically disordered contents than prokaryotes. A quantitative 
and qualitative measurement of the extent of protein disorder in 3484 species with known 
genomes was performed by Xue et al. [2]. Viruses were found to have the widest spread 
of disorder content (from 7.3% in human coronavirus NL63 to 77.3% in avian carcinoma 
virus) in their study. 
Several studies have revealed the possibility of the hypothesis: protein disorder is 
used for signaling because of its unique structural properties. Many bioinformatics 
studies claim that disordered proteins  involve  more in signaling pathway, gene 
regulation, molecular recognition and cell control particularly while structured proteins 
often involve in catalysis, membrane transport and small molecules binding [3-7]. 
Many biological events in which disordered proteins participate are found to be 
regulated by post translational modifications (PTMs) and alternative splicing events 
(ASEs) [8,9]. Fukuchi et al. explored a variety of protein modification events in different 
subcellular localizations and found protein disorder are highly enriched in nuclear 
proteins (47%) compared to mitochondria proteins (13%) [8]. Also, phosphorylation and 
O-linked glycosylation sites were frequently observed to localize in intrinsically 
disordered regions (IDRs). They suspected the O-linked glycans are attached to IDRs in 
order to protect the protein from proteolytic cleavage in the extracellular environment. 
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Besides PTMs, alternative splicing events (ASEs) have been associated with IDRs by 
various laboratories [8,9]. 
1.2. Intrinsic Protein Disorder in Protein-Protein Interactions 
Many proteins execute their biological functions through protein-protein 
interactions.  By binding to interacting partners, proteins can deliver signals to other 
molecules.  For example, hormone neurotransmitters and their receptors trigger various 
signal transduction pathways following their mutual interaction, antibody recognition of 
peptide antigens leads to B-cell activation, and the interaction between G-protein coupled 
receptors and G-proteins leads to the transduction of many biological signals.  
Protein-protein interaction networks underlie a wide variety of biological 
functions, ranging from regulating cell division to responding to external signals. High 
throughput methods have enabled researchers to map out sets of protein-protein 
interactions over entire proteomes. Mapping protein-protein interactions leads to 
networks that are far from random. While most proteins have only a few interacting 
partners, the studies reveal complex networks in which a small number of proteins, called 
hubs, are observed, to have multiple interacting partners.  Indeed, in some cases hubs 
bind to 15, 20, 50 or even more partner proteins.  As expected for such network 
architecture, deletion of a protein with only a few partners is typically less deleterious 
than the deletion of a hub protein [10,11].  
How do such networks arise from simpler precursors?  Other networks of a 
similar architecture arise because “the rich get richer”; units with more connections have 
a higher probability of adding even more connections over time as compared to the units 
with fewer connections.  This suggests that highly connected proteins have special 
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features that facilitate their binding to multiple partners and that facilitate binding to new 
partners that arise through mutation [12]. What are these special features?   
Theoretical arguments [13,14] and experimental data [15,16] suggest that 
unfolded or disordered protein can very readily change shape and thereby easily adapt to 
multiple, distinct partners.  The common involvement of disorder in hub proteins’ 
interactions has been supported by several subsequent studies [17-19]. Intrinsically 
disordered proteins often bind to more than one partner. Thus, we proposed that the 
special feature of hub proteins enabling their binding to multiple partners is likely to be 
intrinsic disorder.  In support of IDPs as being important for binding to multiple partners, 
both hub proteins and their binding partners are observed to be enriched in disorder [19-
21], and many additional studies support these concepts [17,22-31].  
1.3. Characterization of Molecular Recognition Features (MoRFs) and their Binding 
Partners 
With regard to IDP regions involved in binding, various descriptors have been 
used, such as eukaryotic linear motif (ELMs) [32,33], linear motifs (LMs) [34], short 
linear motif (SLiMs) [35,36], regions of increased structural propensity (RISPs) [37], and 
molecular recognition features (MoRFs) [38]. All of these describe similar phenomena, 
despite different approaches used by the various researchers for identification of binding 
segments. The identification of ELMs, LMs, or SLiMs start from sequence pattern or 
motif-based approaches, whereas the identification of RISPs and MoRFs start from short 
regions with binding indicators located within longer regions of predicted disorder. The 
motif-based and algorithmic approaches show significant overlap in their identification of 
their binding sites [34], suggesting that the different approaches associated with the 
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different names are merely emphasizing different aspects of the same types of binding 
interactions.   
Because ELMs, LMs, and SLiMs all involve sequence motifs, these binding 
regions can be identified by simple pattern recognition methods, albeit with a high error 
rate due to their typically short length involving just a few key residues. Predicting 
protein-protein interaction sites in proteins can be used to supplement experimental 
approaches [39,40]. Predicting binding sites by sequence matches to the motifs of ELMs 
[32,33], LMs [34], SLiMs [35,36], or other collections of sequence patterns [41-43] 
provides one strategy for identifying potential binding sites located within IDPs or IDP 
regions. Using sequence characteristics that indicate short binding regions within longer 
regions of disorder offers a second strategy that does not depend on specific motifs, and 
several predictors have been developed that use this second strategy [44-48]. Such 
predictors have been used by experimentalists to help with the identification of binding 
regions within longer regions of disorder [37,49].  
1.4. MoRFs in PDB: Their Length, delta ASA and Secondary Structures 
Table 1 lists the number of MoRFs we collected in each filtering step in our 2008 
and 2012 datasets. The criteria we used for screening MoRFs are slightly different in two 
aspects: the length of MoRF partners and the exact sequence we use for sequence 
alignment. Basically, the MoRF dataset grew about 2.7 folds over the past 4 years. 
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Table 1. Description of MoRF datasets built in 2008 and 2012. 
Data set March 2008 June 2012 
Initial MoRF dataset (5-25) 4289 8084 
MoRF dataset with biological interaction (>400Å
2
) 3837 7064 
MoRF dataset with globular partner 
(>70 vs. > 40) 
3148 6171 
MoRFs mapped to UniProt 
(ATOM vs. SEQRES) 
1805 4839 
 
 
The following Figures (2-4) give us a general overview of our 2008 MoRF dataset 
(4289 complexes) on MoRF length, surface area change upon binding (∆ASA) and 
secondary structure.  
 
 Figure 2. A histogram of MoRF length of the 2008 MoRF dataset. 
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 Figure 3. A scatter plot reveals a positive but not significant correlation between MoRF 
length and surface area change (∆ASA) upon binding.  
 
 
 
  Figure 4. A pie chart of different MoRF types based on their secondary structures.  
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1.5. Validation on MoRFs (Gunasekaran-Tsai-Nussinov Graph) 
Gunasekaran et al. developed a protocol [50] that we modified [38] to indicate 
whether a MoRF is likely to be disordered when unbound. The Gunasekaran-Tsai-
Nussinov graph provides a scale that measures confidence with which one can say 
whether a protein is ordered or disordered. The farther the point, which corresponds to a 
given chain, is from the dividing black line (boundary), the greater the confidence with 
which a protein can be classified into either of the classes. Points above the line 
correspond to disordered chains like Figure 5 shows below. All the 842 MoRFs selected 
form our 2008 MoRF dataset (a non-redundant set) are validated as likely to be 
disordered before the binding events. 
 
 
Figure 5. A Gunasekaran-Tsai-Nussinov graph example (adapted from Bioinformatics 
28, i75-83).  
Disordered 
Ordered 
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1.6. Two MoRF Mechanisms in Hub Proteins 
We further suggested two ways that disorder could be used by hub proteins for 
binding to multiple partners: 1. One region of disorder could bind to many different 
partners (one-to-many binding), so the hub protein itself uses disorder for multiple 
partner binding; and 2. Many different regions of disorder could bind to a single partner 
(many-to-one binding), so the hub protein is structured but binds to many disordered 
partners via interaction with disorder [51]. Since this initial proposal, we [19,22,23] and 
many others [20,21,24-31,52] have provided additional evidence that hubs and/or their 
binding partners are especially enriched in intrinsic disorder, with both the many-to-one 
and one-to-many processes involving the use of intrinsic disorder.   
The C-terminal region of p53 uses disorder to bind to more than 45 different 
proteins and to form a tetramer, but only six of these complexes and the tetramer have 
had their structures deposited in the Protein Data Bank (PDB) [46]. One particular p53 
segment “SHLKSKKGQSTSRHKKLMFKTE” (residues 367-388), which is both an 
ELM and a MoRF and which is located at the C-terminus, morphs into an -helix when 
binding with S100ββ, into a -sheet with sirtuin, into an irregular structure with CREB 
binding protein (CBP) and into another irregular structure with cyclin A2 as a partner 
[46].   
Very different biological processes are transduced via these four different 
interactions involving the same segment of p53:  The CDK2/cyclin A2 complex regulates 
progression of S phase of the eukaryote cell cycle by recognizing diverse but structurally 
constrained target sequences (KXL/RXL motif) from various substrates, including p53 
[53]; deacetylase enzymes like the Sir 2 protein, which is a homologue of Sirtuin, can 
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lead to down-regulation of p53-dependent transcription by binding to the acetylated p53 
peptide on lysine 382 [54]; the recognition of acetylated lysine 382 in p53 by the 
conserved bromo-domain of transcriptional coactivator CBP is very specific, leading to 
the recruitment of p53 acetylation-dependent coactivator following DNA damage and to 
the activation of cyclin-dependent kinase inhibitor p21 [55]; dimeric S100 calcium 
binding protein B can sterically block the phosphorylation and acetylation sites of on p53 
that are critical for the activation important transcription; finally, the peptide derived 
from the region of p53 was found to undergo a disorder-to-order conformational change 
while binding to Ca2+ loaded S100ββ [56]. Thus, this same intrinsically disordered 
segment plays roles in a diverse set of signaling pathways.   
The highly conserved 14-3-3 protein family has been reported to associate with 
over 200 different but mostly phosphorylated proteins [57]. Phosphorylation plays a 
central role in cellular regulation, either by altering a protein’s activity directly or by 
inducing specific protein-protein interactions. Protein phosphorylation events are often 
coupled with domain-binding motifs, highlighting a potential switch-like function of 
phosphorylation. In part, the ability of 14-3-3 to associate with many different proteins is 
the result of its specific phospho-serine/phospho-threonine binding activity. These 
phosphorylation sites are often surrounded by disorder-promoting residues. From this 
observation, a bioinformatics study suggested that over 90% of the 14-3-3 protein 
partners do not adopt a defined three-dimensional structure in total or in part [58]. This 
implies structural disorder in 14-3-3 partners is the key characteristic for promoting this 
binding diversity. But how the 14-3-3 partners have diverged with respect to their 
primary structure and yet still maintain binding to 14-3-3 as an unanswered question.   
12 
 
In the 14-3-3 many-to-one binding example, 3D structures have been determined 
for five different complexes having different disordered sequences, namely a peptide 
fragment from the tail of histone H3, serotonin N-acetyltransferase (AANAT), a phage 
display-derived peptide (R18), and peptides described as motifs 1 and 2  (m1 and m2).  
All five of these peptides associate within a common binding groove in 14-3-3 [46]. 
Within the superimposed structures of the five peptides, the central three binding residues 
show little divergence in backbone locations, but the backbones become more separated 
as one moves away from the central phosphorylated (or negatively charged) residue. This 
divergence is loosely correlated with the sequence similarity. The standard deviation of 
∆ASA for the peptide binding residues also show either end of the central cleft have the 
most binding diversity. Restricted backbone variability in bound 14-3-3 structures 
suggests that a large conformational change in 14-3-3 is not necessary for multiple 
specificities, but some small adjustments at the ends of binding helices may be 
unavoidable. The circular variances of the dihedral angles of residue side chains indicate 
side chain rearrangements also help accommodate different peptide sequences. 
The multiple intrinsically disordered phosphorylated proteins bound by 14-3-3 
regulate a wide range of cellular targets [59]. The diverse cellular processes involving 
these interactions with 14-3-3 include signal transduction, cell cycle control, apoptosis, 
transcriptional regulation, cytoskeleton rearrangements, cell adhesion, chromosome 
maintenance, protein localization, protein trafficking, protein degradation, exocytosis, 
endocytosis, development and stress response [60]. Therefore, molecular recognition by 
14-3-3 proteins highlights the emerging importance of using system-based approaches to 
understand signal transduction event at the network biology level.  
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Many other protein-protein interactions are also mediated by the same many-to-
one binding mechanism. Well known examples include MoRFs that interact with SH3, 
SH2, PDZ and WW domains [61-63]. However, the true extent and diversity of MoRF-
mediated interactions is largely unknown.  
We know of only two atomic resolution comparisons of more than one IDP 
binding to the same partner: two different peptides binding to TAZ1 domain [64] and five 
different peptides binding to 14-3-3 [46,65].   
Our initial work [19,22,23,51] on disorder and protein-protein interactions 
focused on single binding sites that used regions of disorder.  To be more complete, it is 
worth mentioning that, in addition to the one-to-many and many-to-one mechanisms used 
by single sites of disorder for multiple partner binding, hub proteins can also use multiple 
binding domain repeats likely connected by flexible (disordered) linkers [20], or hubs can 
use multiple binding sites one after another in long regions of disorder as we recently 
discussed [66]. Of course these additional, multi-site mechanisms can be multiplexed via 
one-to-many and many-to-one mechanisms, thus leading to extremely complicated 
protein-protein interaction networks.  
1.7. Importance of MoRF Mechanisms in Hub Proteins     
Independent of their roles in hub protein interactions, intrinsically disordered 
proteins (IDPs) lack of specific structures provide the basis for important biological 
functions [67,68] such as signal transduction, cell regulation, molecular recognition, and 
many other functions [3-7,64,69,70]. Many of these disorder-utilizing biological 
functions depend ultimately on disorder-based protein-protein interactions.  Thus, 
understanding the structural basis of protein-protein interactions involving IDPs is 
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important for a wide variety of biological functions, not just as the mechanistic basis for 
hub protein function. 
Both a hub protein’s ability to bind multiple partners and the general importance 
of protein-protein interactions suggest that the use of flexibility for partner binding by 
IDPs and IDP regions is of considerable interest.  However, despite the importance of 
understanding how one disordered region can bind to more than one partner, there have 
been very few structural comparisons at the atomic resolution level, either for one-to-
many binding examples or for many-to-one binding examples.  For the latter, we know of 
only two atomic resolution comparisons of more than one IDP binding to a single partner: 
namely, two different peptides binding to the TAZ1 domain [64], and five different 
peptides binding to 14-3-3 [46].  With regard to the former, we likewise know of just 
three published examples: namely a short segment from HIF1 bound to two partners, 
the TAZ1 domain and the asparagine hydroxylase FIH protein [64],  a short segment 
from the C-terminus of p53 bound to four partners, S100, sirtuin, CREB binding 
protein, and cyclin A2 [46], and a larger collection of various short segments bound to 
multiple partners [71]. 
Our decision to test whether hub proteins depend on disorder was motivated by 
prior experiments showing that conformational disorder enabled one particular protein 
region to bind to multiple partners [72]. We have carried out data mining on the Protein 
Data Bank (PDB) to find additional examples of both one-to-many and many-to-one 
complexes at atomic resolution.  
We have found well over 300 sets that contain segments having the same 
sequence bound to two or more partners, but here we are focusing on unambiguously the 
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same protein bound to highly divergent partners (e.g. partner pairs with less than 25% 
sequence identity), thus reducing the numbers down to 23 sets of segments that bind to 2 
to 9 partners.  The goal is to provide detailed analyses of the conformational changes 
enabling the same disordered segment to bind to more than one protein partner.  Overall 
these data support the view that the flexibility of disordered regions is a significant factor 
in the ability of IDPs to bind to two or more partners.  As we assembled this dataset, we 
also found that alternative splicing events (ASEs) and PTMs were also involved in the 
process of enabling one disordered region to bind to more than one protein partner.  
These latter findings suggest that interplay of multiple factors has participated in the 
evolution of complex protein-protein interaction networks and might be important in the 
development of tissue-specific signaling networks.  
Our data mining of PDB yielded over 500 sets that contain multiple, different 
MoRF segments bound to common binding partners, but here we are focusing on those 
larger domains (greater than 70 amino acids) bound to nonidentical MoRFs, thus 
reducing the number down to 160 sets of domains that bind to 2 to 48 segments. Our goal 
is to look at the detailed binding profiles of many-to-one binding and to perform 
structural analyses on the different binding segments. Two main binding profiles were 
observed in the assembled dataset. The MoRF segments sometimes bind to completely 
independent sites. Alternatively, the segments can bind to overlapping regions, which can 
range from highly similar sites to minimally intersecting sites on the corresponding 
partner. To quantitate the degree of overlap within the 5507 overlapping MoRF pairs in 
our 160 many-to-one set, we estimated the amount of spatial superposition each pair, 
which was expressed as a volume overlap ratio. This measure follows a normal 
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distribution when all the atoms of each MoRF are included. However, if only the 
backbone atoms are included or if the backbone atoms + C-beta atoms are included, then 
the distribution becomes much more asymmetric, showing steady numbers of pairs as the 
overlap ratio increases from very low overlap to almost 50% overlap, at which point the 
number of pairs increases rapidly.  These results suggest that, in our dataset, similar 
binding sites for MoRF pairs are more common than are intersecting binding sites for 
MoRF pairs.  
The detailed findings and results regarding the binding diversity and partner 
selection in protein disorder are described in the following chapters, thus leading to a 
better understanding of MoRF-domain network biology and regulatory mechanisms 
based on IDP regions. We expect that this improved understanding will eventually lead to 
deeper explanations of many cellular and biological processes. Hopefully, the specific 
examples we collected and analyzed in one-to-many, many-to-one and many-to-many 
binding mechanisms in this study will be seen to reveal the complexity and natural beauty 
of the protein interactome in cells.   
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CHAPTER 2 
Materials and Methods 
 
2.1. MoRF Datasets Preparation 
Our disordered hub dataset was extracted from PDB by analyzing the complex 
structures that have short non-globular protein fragments bound to large globular 
structured partners. In this paper, we concentrated on those MoRFs which are short non-
globular protein fragments whose visible residues in crystallographic electron density 
maps included between 5 and 25 residues and binding partners are globular proteins 
greater than 70 amino acids in length. The PDB entries we used were released on March 
28, 2008 and June 19, 2012. 
An interface size (∆ASA) of 400Å2 was used to discriminate biologically relevant 
interactions and non-biological interactions caused by crystal packing contacts in this 
study [73]. The same cutoff was previously chosen by the authors of the protein 
quaternary structure file server (PQS), since the minimal ∆ASA of homo-dimers and 
hetero-dimer are about 370 Å2 and 640 Å2, respectively [74].  
2.2. Characterization of MoRF Clusters that Perform One-to-Many and Many-to-
One Binding 
Besides p53 other MoRFs that bind to two or more partners and that have 
structures in PDB have not been systematically compared to understand how disorder can 
bind to multiple partners. To discover specific disordered regions binding to multiple 
structured partners like p53, we used a Fasta program to align each MoRF sequence to 
the UniProt sequence database. This database encompasses the UniProtKB/Swiss-Prot 
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and UniProtKB/TrEMBL databases. The e-value was set at 1000 while carrying out the 
similarity search. Following that, we only kept those MoRFs which had overlapping 
regions (circled ones in Figure 6) in their parent sequence mapping and used a cluster 
algorithm (wherein at least one residue overlapped with the rest of the MoRFs in the 
same cluster).  
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Figure 6.  A schematic diagram to show how we constructed our (A) one-to-many and 
(B) many-to-one binding dataset by aligning and clustering MoRF sequences from 
complex structures in PDB. 
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2.3. Removal of Redundant MoRFs in MoRF Clusters 
As our research is focused upon those MoRFs from the same disordered region 
which bind to structurally different partners, we used the blastcluster program to remove 
any redundant structured partners in our dataset based on 100% and 25% sequence 
identity. That means that those specific MoRFs are in one disordered region, but they use 
distinct residues to form bonding with different structured partners.  
2.4. Removal of Atypical MoRFs in MoRF Clusters 
After examination of the entire MoRF dataset manually, we found there were 
several unanticipated cases that were not consistent and needed to be removed from our 
dataset. They include the cases involving one MoRF interacting with more than one 
partner in a single PDB entry or a partner molecule which may be a subset of another 
partner in the same cluster.   
2.5. Secondary Structure Assignment on MoRFs 
We classified MoRFs into 4 different types (α, β, ι and complex) based on their 
secondary structure type which has the largest percentage value of the four types 
mentioned above. If there is no clear preponderance of any one secondary type (which is 
at least 1% greater than the other 2 types), we classified it as a complex-MoRF. Only the 
residues on the interface were counted. DSSP was used as the secondary structure 
assignment program here. 
2.6. Sequence and Structure Similarity Analyses 
The root mean square deviation (RMSD) of pairwise proteins was calculated by 
CEalign [75]. The coverage of alignable region is calculated by length of aligned regions 
dividing by average length of all sequences. The transposed coordinates and multiple 
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structure alignments were generated by MultiProt algorithm [76] using the complex 
structures including both MoRF and partner. Sequence identity calculations are based on 
the structure alignments. The sequence identities of MoRFs within many-to-one clusters 
were obtained from PRALINE multiple sequence alignment server [77]. The overlap 
ratio for each MoRF pair was calculated as the formula below, where V is the volume of 
the molecule. Vij means the union volume of MoRF i and MoRF j.  
                   
         
         
                           
Both residues in each aligned pair were compared to see if they are both in the 
binding or nonbinding region. The alignment will be considered identical only when the 
position in both proteins is assigned in the same class: either binding or nonbinding. For 
the case with more than 2 partners, we averaged all the identities together. Those aligned 
residues not consistent with their binding/nonbinding status (one is on binding region, but 
the other one is not) will be classified into another category that didn’t show on our 
results. Here, those residues with higher solvent surface changes (greater than 1 Å
2
) will 
be considered as interacting residues. Error bars that represent the 95% confidence 
interval (CI) of a mean are approximated from 3000 random samplings with replacement 
generated by the bootstrapping method. The molecular images in Figures were generated 
by PyMol software. 
2.7. Peptide-Protein Interaction Annotation 
Several immune-related protein interactions are considered as peptide-protein 
interaction.  Interactions involving in MHC molecules, antibodies and T-cell receptors 
within our dataset are separated from other protein-protein interactions.  
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2.8. SCOP Classification on MoRF Partners 
Structural Classification of Proteins (SCOP) is a database providing detailed and 
comprehensive annotations of the structural and evolutionary relationships between the 
proteins whose structure are known in PDB. The SCOP classification of proteins was 
constructed manually by visual inspection and structural comparison with assistance of 
tools. There are four levels existing in the SCOP hierarchy. Each protein can be assigned 
to reflect both structural and evolutionary relatedness.  
1.   Family: clear evolutionarily relationship (>30% pairwise sequence identity). 
2.  Superfamily: Probable common evolutionary origin (low sequence identity with 
structural and functional features suggesting a common evolutionary origin). 
3.   Fold: Major structural similarity (same major secondary structures in the same 
arrangement and topological connection). 
4.   Class: Types of folds, including all alpha, all beta, alpha and beta (a/b), alpha and 
beta (a+b), multi-domain proteins and so on. 
SCOP 1.75 release (23 Feb 2009) was applied to our MoRF dataset on partner 
side to see if there is a structural preference for MoRF partner selection. There are 1195 
folds, 1962 superfamilies, 3902 families, 38221 PDB entries and 110800 domains in the 
current release (excluding nucleic acids and theoretical models). 
2.9. Network Analysis of MoRF Datasets 
A summarized protein interaction network between the 510 human proteins in our 
MoRF set was generated by the Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING). STRING is a database of known and predicted protein 
interactions based on demonic context high-throughput experiments, conserved 
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coexpression and previous knowledge. The current STRING 9.05 database covers 
5,214,234 proteins from 1133 organisms. The edges between MoRF nodes in the graph 
are based on the method of known and predicted interactions according to the following 
sources: neighborhood, gene fusion, co-occurrence, co-expression, experiments, 
databases, text mining, and homology. The MoRFs in the generated interaction network 
by STRING is highly connected which indicates MoRFs do perform functions 
appropriate for hubs. 
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CHAPTER 3 
Binding Diversity of Intrinsic Protein Disorder 
 
3.1. One-to-Many Binding 
We identified 4289 MoRFs from the PDB based on their sequence length (5 to 25 
residues). Of these, 452 complexes with small surface areas of interaction (<400 Å
2
) were 
eliminated due to uncertainty regarding the biological significance of the interactions. An 
additional 689 complexes were excluded because their partners were nonglobular (length 
< 70 residues).  
In order to identify overlapping MoRFs, MoRF sequences were mapped back to 
their parent sequences. A short segment will give exact matches to many unrelated 
sequences. Since many of the MoRFs are short, only 1805 of the remaining 3148 MoRFs 
could be unambiguously mapped in an automated fashion to their parent sequences in 
UniProt database. In addition, the parent sequence information are not always annotated 
in PDB. Based on the overlapping regions in parent sequence mapping (at least one 
residue), 298 MoRF sets with multiple partnerships were obtained. Structurally redundant 
partners were discarded from our final dataset based on imposing an upper bound of 25% 
pairwise sequence identity for every pair of partners.  
Finally, 23 MoRF clusters with 61 partners were further confirmed by manual 
inspection to ensure that short peptides were bound to globular partners. Thus, for the 
dataset investigated herein, each MoRF associates with an average of 2 to 3 distinct 
partners. A summary of the development of the dataset is given in Table 2. Figure 7 is a 
bubble chart showing the 3-way relationship between MoRF length (x-axis), MoRF count 
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(y-axis) and cluster count (size of bubbles) in the 23 MoRF clusters. The 23 MoRF 
examples are listed in Table 3. The previous two partnerships involving HIF1 was not 
found in this study because the length of the peptide, 51 amino acids, exceeded the upper 
bound of 25 residues used in this study. Here, peptides are defined to have lengths in 
between 5 to 25 residues and domains are defined to have more than 70 (2008 MoRF 
dataset) or 40 (2012 MoRF dataset) residues. On the other hand, note that the previously 
described four partnerships involving the carboxy terminal tail of p53 were all found in 
our dataset [78], showing that our overall strategy found a previously known example the 
length of which was between our upper and lower thresholds.  
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Table 2. Description of one-to-many MoRF dataset. 
Data set MoRFs Clusters MoRFs 
per cluster 
Initial MoRF dataset (5-25)
 a
 4289   
MoRF dataset with biological interaction (>400Å
2
)
 b
 3837   
MoRF dataset with globular partner (>70)
 c
 3148   
MoRFs mapped to UniProt sequence database
 d
 1805   
MoRFs with overlapped region in mapping
 e
 1493 298 5.01 
MoRFs without 100% sequence identity in partners 248 87 2.85 
MoRFs without 25% sequence identity in partners 214 77 2.78 
MoRFs without atypical cases
 f
 61 23 2.65 
a
MoRFs with 5 to 25 residues are the focus of this study.  
b
400 Å
2 
cutoff was set to filter out the spurious interactions caused by crystal contacts. 
c
Binding partners of MoRF are supposed to be globular proteins having more than 70 residues to fold into a 
certain conformation. The excluded ones includes interactions between short domain like SH3, 
chromodomain, A/B chain of insulin , Gramicidin-form ion channels, peptides forming amyloid-like fibril, 
alpha-helical coiled coil, de novo proteins. 
dMost MoRFs can’t be mapped to UniProt are with 5 to 9 residues in length. 
e
MoRFs having one or more overlapping residues  with each other. 
f
Atypical cases include, for example, one MoRF bound more than one partner the same PDB entry and 
partners with subsequences that exactly match the entire sequence of another partner. 
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Figure 7. A bubble chart shows a 3-way relationship between MoRF length, MoRF count 
and cluster count in our one-to-many MoRF set.  
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Table 3. Twenty-three examples of MoRFs and their secondary structures. 
MoRF examples  Bound conformation Partners MoRFs 
 N Helix Sheet Coil Complex RMSD Coverage PTM AS 
8 MoRFs with differently-folded partners 26       11 1 
1. Histone H3 – N-term I 9 0 0 9 0 7.07 0.21 5 - 
2. p53 – near C-term 4 1 0 2 1 6.80 0.39 1 
1
N 
3. CTD of RNA polymerase II 3 0 0 3 0 8.35 0.26 3 - 
4. Angiotensin  2 0 0 2 0 7.74 0.27 0 - 
5. HIV envelope glycoprotein 2 0 0 2 0 4.16 0.41 0 - 
6. Histone H3 - N-term II 2 0 0 2 0 8.25 0.22 2 - 
7. Vasopressin 2 0 0 2 0 8.69 0.37 0 - 
8. p53 – near N-term 2 2 0 0 0 6.18 0.62# 0 
1
Y 
15 MoRFs with similarly-folded partners 35       2 4 
9. Nuclear receptor coactivator 1 & 2 5 2 0 2 1 3.94 0.92 0 - 
10. Nuclear receptor corepressor 2  3 2 0 1 0 3.43 0.85 0 
1
TS 
11. TRAP 220 3 3 0 0 0 3.05 0.91 0 
2
Y 
12. Nuclear receptor coactivator 1 2 2 0 0 0 5.49 0.85 0 - 
13. BAK peptide 2 2 0 0 0 5.50 0.73 0 
1
N 
14. Nuclear receptor 0B2 – N-term 2 2 0 0 0 3.74 0.86 0 
1
N 
15. Troponin I, cardiac muscles 2 0 0 1 1 3.01 0.79 0 - 
16. Nuclear receptor 0B2 – C-term 2 1 0 1 0 3.88 0.80 0 
1
N 
17. Cell death protein GRIM 2 0 2 0 0 2.33 0.79 0 - 
18. Beclin-1 2 2 0 0 0 4.10 0.84 0 - 
19. Histone H4 2 0 0 2 0 3.93 0.50* 0 - 
20. Bcl-2-like protein 11 (Bim) 2 2 0 0 0 2.72 0.90 0 
1
Y 
21. Amyloid beta A4 protein 2 0 0 2 0 2.93 0.84 0 
1
Y 
22. Rhodopsin 2 2 0 0 0 4.25 0.86 0 - 
23. DNA repair protein RAD9 2 0 0 2 0 3.53 0.36* 2 - 
N: numbers of MoRFs in the set; PTM: post-translation modification; AS: alternative splicing; TS: tissue-
specific alternative splicing. 
#
Although most residues within the two partners can be roughly aligned 
together, their individual structure varies a lot. *Within these two sets, the coverage of good alignments is 
low because one partner is a sub-domain of the other partner but with low sequence identity. 
1
MoRFs are 
from human; 
2
MoRFs are from mouse; -MoRFs are from other species. Underlined MoRFs are in 11 sets. 
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Most sets contain one MoRF interacting individually with two partners, but six of 
the sets have more than two partners. These are the N-terminus of histone H3, nuclear 
receptor coactivator 1 and 2, the C-terminus of p53, the NR corepressor 2, the thyroid 
receptor associated protein 220, and the carboxyl-terminal domain (CTD) of RNA 
polymerase II. Since MoRFs in the NR coactivator 1 and 2 share similar sequences and 
can be mapped to the same parent sequence, our method clustered them together as a 
single set. Most clusters have MoRFs with similar secondary structures in different 
complexes. Only five of them exhibit a mixture of different secondary structures (Table 
3).   
The goal here was to find the same MoRF sequence bound to structurally distinct 
partners, so partners having low sequence identity were chosen. A sequence identity of 
25% was chosen as the upper bound because proteins with sequence identities higher 
than this value are almost always similar in structure [79]. Nevertheless, even though the 
partners of each MoRF set were selected to have low sequence identity, several partner 
conformations turned out to exhibit structural similarity. Based on the structure alignment 
of their partners, the 23 MoRF sets can roughly be grouped into 15 MoRFs with 
similarly-folded partners (with ~19% sequence identity on average) and 8 MoRFs with 
differently-folded partners (with ~10% sequence identity on average). Notice that MoRFs 
with differently-folded partners apparently prefer to form irregular secondary structure 
upon binding, while MoRFs with similarly folded but sequence diverse partners tend to 
prefer to form helix or sheet (Table 4).  
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Table 4. The combination of secondary structure types in the 23 MoRFs. 
Secondary structure Clusters Similarly-folded 
partners 
Differently-folded 
partners 
α + β + ι +Complex 0 0 0 
α + β + ι 0 0 0 
α + β + Complex 0 0 0 
α + ι + Complex 2 1 1 
β + ι + Complex 0 0 0 
α + β 0 0 0 
α + ι 2 2 0 
α + Complex 0 0 0 
β + ι 0 0 0 
β + Complex 0 0 0 
ι + Complex 1 1 0 
α 8 7 1 
β 1 1 0 
ι 9 3 6 
Complex 0 0 0 
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Two predictors, ANCHOR [47] and MoRFpred [48], have been developed to 
predict partner binding sites within longer regions of disorder.  Application of these 
predictors to the MoRF-containing sequences shows that, while both predictors typically 
indicate binding sites corresponding to the observed MoRFs, neither predictor is 
particularly accurate with respect to the locations of the binding sites (data not shown). 
Interestingly, the locations of the MoRFs with similarly-folded partners are predicted 
with slightly greater accuracy by both predictors as compared to the locations of MoRFs 
that bind to differently-folded partners. 
3.1.1. Fifteen MoRF Sets with Similarly-Folded Partners 
Among the 15 MoRFs with partners having similar folds, similar binding profiles 
and common interacting residues were observed. Partner pairs within 11 of these MoRFs 
have both a relatively low RMSD and a relatively good structural alignment. The RMSD 
values and the fraction of the total residues that gave good structural alignments were 
estimated for the sets of partners for the 18 MoRFs.  The 11 sets that had both a relatively 
low RMSD (2.33 to 5.49 Å) and a relatively high fraction with good structural alignment 
(termed coverage; values between 0.79-0.91), are given in Table 5. The partners of the 
DNA repair protein RAD9 have a reasonable RMSD (3.53) but a low coverage (0.36). 
This protein was not discarded because one of the partners had a large, non-alignable 
extra domain that was responsible for the low coverage.   
In order to answer if having similar binding patterns mean MoRFs tend to bind a 
specific set of residues on partners, we analyzed the sequence identities of binding 
regions and nonbinding regions on partner side to determine whether the interacting 
residues are more selected during evolution (Table 5). Those interacting residues tend to 
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be selected to form connection with same MoRF using similar binding patterns as we 
expected. The sequence conservation of the binding region is significantly higher than 
those in other parts of the protein.  The mean sequence identity for structurally aligned 
binding and non-binding residues are 42±6% and 20±3%, respectively, within these 11 
sets. Binding residues, which are usually on the surface, have about 2.5 fold higher 
sequence identity than nonbinding surface residues, indicating that these interactions are 
likely to be biological significant. These averages were taken over structurally matching 
residues. In comparison, for a collection of enzymes with ~ 25% sequence identity, the 
active site residues exhibit sequence identities in the range of 43% to 70% [80]. 
Interestingly, the binding residues being discussed here for several of the proteins show 
sequence identities that overlap the lower part of the observed range for enzyme active 
site residues, which are known to have a high tendency to be conserved. Note also that 
the binding residues show a much higher conservation for the aligned residues as 
compared to the nonbinding surface residues (column B versus NB_E) or to the 
nonbinding buried residues (column B versus NB_B). 
For the same MoRF bound to structurally similar partners, only slight 
conformational changes of MoRF side chains were observed, whereas the backbone 
conformations of the same MoRF between various complexes are relatively uniform. 
Many features of the various interactions indicate that the disordered binding segments 
were likely to have been disordered before binding. Hence, these results also add further 
weight to the existence and function of intrinsically disordered regions inside cells. 
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Table 5.  Sequence identities of binding regions and nonbinding regions in partners of 11 
disordered hub examples based on MultiProt structural alignment. 
 
Disordered hub examples  B  NB  NB_B NB_E Overall 
Nuclear receptor corepressor 2  0.36 0.17 0.22 0.15 0.21 
TRAP 220 0.51 0.23 0.26 0.19 0.24 
Nuclear receptor coactivator 1 0.62 0.16 0.22 0.08 0.16 
Nuclear receptor 0B2 – near N-term 0.47 0.20 0.30 0.16 0.19 
Troponin I, cardiac muscles 0.36 0.34 0.62 0.29 0.25 
Nuclear receptor 0B2 – near C-term 0.27 0.16 0.13 0.25 0.12 
Cell death protein GRIM 0.33 0.28 0.60 0.09 0.26 
Beclin-1 0.45 0.17 0.26 0.06 0.17 
BCL-2-like protein 11 0.44 0.16 0.26 0.11 0.21 
Alzheimer’s disease amyloid A4 protein 
homolog 
0.33 0.19 0.33 0.11 0.15 
DNA repair protein RAD9 0.43 0.27 0.33 0.11 0.07 
 0.42±0.06 0.20±0.03 0.26±0.05 0.16±0.03 0.19±0.04 
The values in columns labeled B, NB, NB_B and NB_E give the averages of pairwise 
sequence identities of binding, nonbinding, nonbinding buried, nonbinding exposed 
residues of the specific MoRF partners based on structure alignments, respectively. The 
value in Overall column gives the sequence identity of all residues based on sequence 
alignment.    
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It is fascinating that 5 of 11 disordered hub examples belonged to the family of 
coregulatory proteins of nuclear receptor (NR), including thyroid receptor associated 
protein 220 (TRAP 220). Our dataset indicates that protein disorder is involved in 
coregulatory proteins of nuclear receptors (NR) such as coactivators and corepressors, 
making it possible for them to perform one-to-many signaling and to function as 
disordered hubs. The nuclear receptors (NRs) are a super-family of proteins, associated 
with other coregulatory proteins involved in the direct mediation and control of the 
expression of specific gene transcription in response to sensing the presence of hormones 
and other molecules. Recent data shows that, in addition to direct activation of the basal 
transcription machinery, nuclear receptors inhibit or enhance transcription by attracting 
an array of coactivator or corepressor proteins to the transcription complex.  
NRs may be classified into two broad categories according to their mechanism of 
action and subcellular distribution in the absence of ligands. Ligands bind to type I NRs 
in the cytosol resulting in the dissociation of heat shock proteins, the formation of homo-
dimers, translocation from cytoplasm into the cell nucleus, and binding to hormone 
response elements. Type I NRs include NR subfamily 3, which encompass androgen 
receptors, estrogen receptors, glucocorticoid receptors and progesterone receptors. Type 
II NRs, in contrast to type I NRs, are retained in the nucleus and heterodimerize upon 
binding to DNA in the absence of a ligand, when type II NRs are usually bound to a 
corepressor. Ligand binding to type II NRs triggers the dissociation of the corepressor, 
leading to the initiation of transcription by the coactivator. Type II NRs include NR 
subfamily 1, and receptor molecules such as retinoic acid receptor (RAR), retinoid x 
receptor (RXR), thyroid hormone receptor (TR) and vitamin D receptor (VDR).  
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Peroxisome proliferator-activated receptor-binding protein (PPAR or PBP), also 
known as thyroid hormone receptor-associated protein 220 (TRAP 220), is an anchor for 
multi-subunit mediator transcription complex. It functions as a transcription coactivator 
for nuclear receptors. These coactivator proteins often exhibit histone acetyltransferase 
(HAT) activity, which weakens the association of the histone to DNA, therefore 
promoting gene transcription. Three MoRFs in PBP have been found to be involved in 
multiple interactions with various type II nuclear receptors, such as vitamin D3 receptor 
(VDR), retinoic acid receptor-beta (RAR-beta) and retinoid x receptor-alpha (RXR-
alpha) in our dataset. RAR or VDR, when forming a heterodimer with RXR, can bind to 
hormone response elements, forming a complex with corepressor protein in the absence 
of any ligands. When a ligand acting as agonist binds to RAR or VDR, it results in the 
dissociation of the corepressor and recruitment of coactivator which in turn, promotes 
transcription of downstream target gene. 
When gene transcription is repressed by nuclear receptors, it is mediated by 
interactions with corepressor proteins. This reaction, in turn attracts histone deacetylases 
(HDACs) to the chromatin, triggering the strong binding of histone to DNA; thus 
repressing gene transcription. The antagonist further reinforces the binding of corepressor 
to the nuclear receptor. MoRF mechanisms are also involved in the down regulation of 
target gene expression when the nuclear receptor corepressor 2 binds to related nuclear 
receptors such as peroxisome proliferator activated receptor (PPAR), estrogen related 
receptor gamma (ERR-gamma) and progesterone receptor (PR) [81-83].  
In the previous two examples, such coregulatory proteins can interact with various 
receptors with low sequence identity but high structure similarity using the same MoRF 
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region. The configurations of secondary structures in those MoRFs bound to receptors are 
also comparable. Further experiments and analyses provided us more detailed and 
specific explanations regarding how disordered regions facilitate the binding diversity in 
different complex structures. The analyses of solvent surface area profiles from the 
examples with structurally different partners, shows different interfaces accommodate a 
variety of binding partners and those overlapping residues in interfaces bind to different 
molecules to varied extents. Otherwise, analogous binding profiles were observed within 
our 11 examples with similar partnerships.  
Three examples were chosen from our 11 sets in order to assess in more detail 
how a disordered region uses its conformational flexibility to form interactions with 
similar but not identical binding pockets. The three examples can be described as an α-
MoRF, a β-MoRF and an irregular-MoRF corresponding to the thyroid receptor 
associated protein 220 (TRAP220), the cell death protein GRIM and the Alzheimer’s 
disease amyloid A4 protein homolog, respectively. Figure 8 shows the interacting 
residues and binding sites of the three selected cases.   
Figure 8.A shows four important residues (M5, L6, L9 and L10) on TRAP220 
stretching into the clefts on the surfaces of receptor proteins with small structural 
variations.  On the contrary, those residues on the non-buried side of the α-MoRF have 
larger conformation fluctuations over the three complexes. 
  Alanine 1 and tyrosine 4 contribute most of the buried surface areas to the 
interaction of GRIM and IAP1 (Figure 8.B). The tyrosine side chain makes a huge 
rotation to fit distinct cavities of IAP1 while the backbone’s -sheet conformation and 
key interactions didn’t change too much (Figure 8.B.1 and 8.B.2).  
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The MoRF in amyloid A4 protein is mostly coil but has local regions that could 
be classified as sheet and helix according the DSSP.   Its central region (NPTY) adopts 
coiled conformation and maintains comparably similar structure (colored in black) in 
both complexes (Figure 8.C). The N-terminus (NGYE) of the green MoRF (Figure 8.C.1) 
stays in a coiled structure while the N-terminus of the red MoRF in (Figure 8.C.2) turns 
into β-strand to form an anti-parallel β-sheet with another strand on DAB1 protein. The 
spatial arrangement of a tyrosine 4 was observed to change substantially, suggesting that 
this change may facilitate the binding to two different surfaces by the same sequence. 
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Figure 8. Conformational changes and variations of an identical MoRF binding to its structure-homologous 
partners from the three selected examples. Different MoRFs are shown in different colors. (A) A fragment 
from TRAP220 forming α-MoRFs to associate with VDR, RAR-beta and RXR-alpha. Those residues on 
the exposed side of helixes are colored in black. (B) The binding sites of a β-MoRF from GRIM and 
apoptosis 1 inhibitor (IAP1). (C) The irregular-MoRF in amyloid A4 protein adapts a highly flexible 
structure to accommodate the binding pockets of DAB1 and X11. Four structurally constrained residues 
with lowest RMSD are shown in black. 
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In addition to gathering general evolutionary information for the whole interfaces 
that MoRFs associate with, some further calculations were carried out on the same three 
selected examples in order to explore more details at the residue level. We compared the 
partner residues with which each MoRF residue associates to determine if partner residue 
variability correlates with overall conformational variation of MoRF itself (Figure 9.A, 
9.B and 9.C). Our hypothesis was: the more diverse the amino acids with which a MoRF 
residue associates, the greater the structural variability of the MoRF backbone. However, 
the correlation analyses between diversity of partner residues (not shown in Figure 9) and 
averaged root mean square standard deviation (RMSD) on C-alpha atom (line plots in 
Figure 9) did not show an obvious and strong correlation. While our particular hypothesis 
was not supported, Figure 9 nevertheless contains interesting summary information 
regarding the changes that are observed when one MoRF binds to multiple partners.  
Note alternating burial and nonburial of residues (Figure 9.A); this pattern can be 
traced to the -helical structure (e.g. an -MoRF) of the thyroid receptor associated 
protein 220.  Also notice that the buried residues are more hydrophobic, and, except for 
proline, the nonburied residues are more hydrophilic. While hydrophobic, proline is often 
found on the surfaces of proteins and, furthermore, frequently occupies positions near the 
amino-terminal ends of helices. Based on our data, prolines compare richly in MoRFs 
and other disordered regions with ordered regions; however, there is no significant 
difference between MoRFs and other disordered regions. We speculate that proline serves 
as a structure breaker and disorder-promoting residue, playing an important character to 
maintain MoRF regions’ flexibility until the binding events. 
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Figure 9. Binding surface area profiles (bar graphs), averaged RMSD (line plots), and important 
interacting residues with various globular partners (right) calculated on each residue from the three 
selected MoRF sets: (A) α-MoRF: thyroid receptor associated protein 220, (B) β- MoRF: Cell death 
protein GRIM and (C) irregular-MoRF: Alzheimer’s disease amyloid A4 protein homolog. Notice in 
group (C) the specific interactions between 2 aromatic groups that oriented themselves orthogonally.  
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Several interesting points were found from the sequence and structure analyses of 
the two residues with the greatest contributions of solvent surface area in the GRIM-IAP1 
interaction (Figure 9.B). Although the side chain of alanine 1 is relatively small, a fairly 
large area becomes buried into the interface. More detailed analysis shows that, for this 
residue, not only the side chain participates the formation of interaction, but backbone 
atoms also play a significant role. 
Big rotations on side chains also related to higher backbone structure variations, 
such as the cases on L9 in the α-MoRF (Figure 9.A), Y4 in β-MoRF (Figure 9.B) and Y4 
in irregular-MoRF (Figure 9.C). The low RMSD of P7 in the irregular-MoRF example 
(Figure 9.C) may correlate with its capping function in the edge of helix in the X11 
protein. 
 Figures 10 and 11 show another two examples for which the flexibility needed to 
accommodate different partner surface features is manifested as side chain rotations. 
Lysine in nuclear receptor corepressor 2 has different conformations to stretch into the 
opposite cleft in three complexes to form the associations between the three receptors 
(Figure 10). Histidine and arginine in nuclear receptor coactivator 1 (NCOA1) and 2 
(NCOA2) also act in a similar way in Figure 11. Here, the two different proteins NCOA 1 
and 2 are grouped into one cluster in our dataset because both of them have similar 
conserved binding sequences containing LxxLL motifs (“HKILHRLLQD” and 
“HKILHRLLQE”) like other NR-boxes [84]. The side chain conformations of the three 
leucine residues stay nearly the same except for the ones that interact with the androgen 
receptor.  
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This example demonstrates that the same proteins can be involved in both one-to-
many and also many-to-one binding, thus raising the level of network complexity and 
leading to multi-protein regulatory complexes that can respond to environmental signals. 
Comparing our one-to-many dataset described herein with our many-to-one dataset (will 
discuss in 3.2) reveals that, of the 23 examples in Table 3, there are 12 cases of proteins 
involved in both one-to-many and many-to-one binding. That is, 12 of the MoRFs in 
Table 3 bind to a structured partner that also binds to additional MoRFs having different 
sequences. Since our identification of one-to-many and many-to-one examples did not 
involve any steps for identifying MoRFs involved in both mechanisms, we find this 
number of 12 of 23 involved in both mechanisms to be quite high and to suggest that 
such dual use of both mechanisms is likely to be a very common feature of protein-
protein interaction networks.    
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Figure 10. MoRFs in nuclear receptor corepressor 2 bind to 3 different but structurally 
similar nuclear receptors. (A) Estrogen-related receptor gamma (with α-MoRF in 2GPV), 
(B) Progesterone receptor (with α-MoRF in 2OVH), (C) Peroxisome proliferator 
activated receptor (with ι-MoRF in 1KKQ) and (D) The charged residues of the core 
MoRF region rotate more in the superimposition of the 3 complexes. 
An interactive view: 
http://imolecules3d.wiley.com:8080/imolecules3d/review/7RE6UdLGVvApooD5ECvQC
KkGKHJKP7qdI7ZN22baIqoUGGY2LAR911FxPS6QN17b689/1288 
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Figure 11. The diagram shows a variety of interactions of MoRFs with highly similar 
sequences in nuclear receptor coactivator 1 and nuclear receptor coactivator 2. (A) ι-
MoRF in nuclear receptor coactivator 2 interacts with androgen receptor (1T65). (B) α-
MoRF in Glucocorticoid receptor-interacting protein1 (alternative name of NCOA2) 
interacts with estrogen receptor (1L2I). (C) complex-MoRF in Nuclear receptor 
coactivator 1 isoform 1 interacts with orphan nuclear receptor NR1I3 (1XV9). (D) α-
MoRF in nuclear receptor coactivator 1 interacts with bile acid receptor (2O9I). (E) ι-
MoRF in nuclear receptor coactivator 1 isoform 3 interacts with orphan nuclear receptor 
PXR (3BEJ). (F) The 3 Leucine residues of the LxxLL motif are superimposed well in 
the 5 complexes. 
An interactive view: 
http://imolecules3d.wiley.com:8080/imolecules3d/review/7RE6UdLGVvApooD5ECvQC
KkGKHJKP7qdI7ZN22baIqoUGGY2LAR911FxPS6QN17b689/1289  
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In summary, NCOA binding molecules include many kinds of nuclear receptors, 
including androgen receptor (AR), estrogen receptor (ER), nuclear receptor subfamily 1, 
group I member 3 (NR1I3/CAR), bile acid receptor (BAR) and pregnane X receptor 
(PXR) [85-89].  
3.1.2. Eight MoRF Sets with Differently-Folded Partners 
Eight MoRFs in our dataset converted into significantly different conformations 
to fit onto the surfaces of structurally different molecular partners. For these examples, 
only a small portion of their partners’ residues can be structurally aligned. We selected 
the three examples with the largest number of partnerships (p53, RNA polymerase II 
(RNAP II) and histone H3) to illustrate the variable buried surface area of each MoRF 
residue upon diverse binding (Figure 12). 
Charged residues (R, H and K), aromatic residues (F and Y) and phosphorylation-
related residues (S, T, Y, H, R, K) in MoRF regions vary substantially in their 
contributions to binding different partners. In contrast, proline contributions to the 
different interfaces involving RNAP II remain relatively stable. Unlike MoRFs with 
similarly folded partners, which generally use their various residues in quite similar ways 
to associate with relatively conserved interacting residues, each partnership within this set 
utilizes conformationally distinct MoRFs and different residues or the same residues with 
different degrees of burial in their associations with their very distinct partners.  That is, 
the same MoRFs show large variability in their side chain burial and exposure and even 
shifts in the binding region when binding to structurally divergent partners.   
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Figure 12. The profiles of solvent surface area changes within 3 selected MoRF clusters 
with structurally different partners: (A) p53, (B) RNAP II and (C) H3. The Y axis gives 
the change in surface area of each entire residue upon binding, while the X axis gives the 
residues.  
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In addition to differential side chain burial and rotations, PTMs are also observed 
to be associated with the conformational alterations that are observed when the same 
MoRF binds to different partners, especially for those MoRFs that bind to structurally 
distinct partners. That is, of the 26 complexes involving differently-folded partners, 11 
have posttranslationally modified residues.  On the other hand, for the MoRFs with 
similarly folded partners, just 2 of the 35 complexes contain PTMs.   
The C-terminus of p53 illustrates the conformational changes of a single MoRF 
within different partnerships. It was observed to transform either into a complex MoRF, 
an ι-MoRF (irregular MoRF), or an α-MoRF (helix), in four different structures in our 
dataset (Figure 13). The complex MoRF is composed of 3 residues of -strand and 3 
residues of coil and was classified as a β-MoRF in our previous work [78].  This change 
from the previous work arose because here we use automated secondary structure 
assignment (DSSP), whereas the previous work used the crystallographer’s assignment of 
secondary structure.   
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Figure 13. Four different biological molecules interact with C-terminus of p53. (A) 
Sirtuin: an NAD-dependent deacetylase (with complex-MoRF), (B) Cyclin A2 (with ι-
MoRF), (C) CREB binding protein (with ι-MoRF), and (D) S100 calcium-binding protein 
(α-MoRF).  In the sequence alignments, a residue having a posttranslational modification 
in PDB is indicated in red.   
 
  
A. Sirtuin                   H K K L M F      
B. Cyclin A2               S R H K K L M F K     
C. CREB BP    S H L K S K K G Q S T S R H K K L M F K     
D. S100ββ    S H L K S K K G Q S T S R H K K L M F K T E   
p53/1-393 366   S S H L K S K K G Q S T S R H K K L M F K T E G 389 
C. CREB BP & p53                                 D.  S100ββ & p53                              
    
A. Sirtuin & p53                                       B.  Cyclin A2 & p53                           
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Although the two other MoRFs, RNAP II and H3, with distinctly folded partners 
have coiled structures for all of their 3 and 9 complexes, respectively, the backbone 
conformations differ markedly between any two pairs of structure.  
The MoRF in the carboxyl-terminal domain (CTD) of RNAP II facilitates several 
enzymes to make post-transcriptional and post-translational modification by binding 
(marked in red in Figure 14). The CTD in RNAP II is composed of up to 52 heptapeptide 
repeats (YSPTSPS) which are important for polymerase activity [90]. Efficient capping, 
splicing and polyadenylation of mRNAs all require the CTD portion of RNAP II. For 
example, the CTD small phosphatase 1 (CTDSP1) catalyzes the dephosphorylation of Ser 
5 within the tandem 7 residues repeats, causing the initiation of RNA polymerase II 
transcription (Figure 14.A) [91]. The Ser 2-phosphorylated CTD binds to a CTD-
interacting domain (CID) in protein 1 of cleavage and polyadenylation factor I (PCF11), 
which is essential for transcription elongation 3’ and RNA processing (Figure 14.B) [92]. 
The mRNA capping enzyme (mRNA CE) is recruited to the transcription complex, 
catalyzing its reaction through the binding of the phosphorylated Ser 5 in carboxyl-
terminal domain (CTD) of RNA polymerase II (Figure 14.C) [93]. The capping 
modification is helpful in the recognition and attachment of mRNA to the ribosome as 
well as protection from exonucleases.  
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Figure 14. The MoRF mechanism plays a role in mediating interactions involving the 
CTD of RNA polymerase II. (A) CTD small phosphatase 1(with ι-MoRF), (B) protein 1 
of cleavage and polyadenylation factor I (with ι-MoRF), (C) mRNA capping enzyme 
alpha subunit (with ι-MoRF), and (D) Similar bends near Pro 1700 occurs in all three 
bound MoRFs. In the sequence alignments, residues in red indicate residues with PTMs 
in PDB. 
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The three bound MoRFs in RNAP II all seem to exhibit a bend at a similar 
location. To gain greater insight, these three MoRFs were structurally aligned (Figure 
14.D). Two of the MoRFs (bound to PCF11 and mRNA CE-α) show very similar 
backbone traces with bends at P1700. The third MoRF (bound to CTDSP1) also shows a 
bend near P1700, but the backbone trace and location of the bend relative to P1700 are 
different from the other two examples (Figure 14.D).    
Since these sequences typically contain just one MoRF binding site for multiple 
partners, this raises the possibility that partner competition for the single site could be an 
important regulatory feature these binding interactions.  In contrast, for the CTD of 
RNAP II, the MoRF sequence is repeated more than 50 times. These MoRFs may adapt 
different structures as they bind alternative partners. The interplay between partner 
competition and repeated binding sites may provide a mechanism for subtle and tunable 
regulation of MoRF / partner interactions. 
The MoRF in Histone H3, which contains the maximal number of partners in our 
dataset, interacts with nine structurally different partners using residues from 2 to 22 in 
the sequence (Figure 15).  Even though all nine MoRFs are classified as coiled structures, 
some residues within the MoRF region form helical or strand-like structures upon binding 
to the different partner proteins. Among the nine binding partners of the N-terminal tail 
of histone H3, there are several enzymes that are implicated in post-translational 
modifications. This N-terminal tail that protrudes from the globular nucleosome core can 
undergo several different types of epigenetic modifications that influence cellular 
processes. These modifications include the covalent attachment of methyl or acetyl 
groups to lysine and arginine amino acids and the phosphorylation of serine or threonine. 
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Some of these modifications are included in our data set and characterized in Figure 15 
(with the modified residues marked in red).   
The double Tudor domain of JMJD2A, a Jmjc domain-containing histone 
demethylase, binds methylated Lys 5 on Histone H3. This complex functions as a 
transcription repressor (Figure 15.A) [94]. The DNA-methyltransferase 3-like 
(DNMT3L) protein recognizes the histone H3 tails with unmethylated Lys 5 and 
stimulates de novo DNA methylation by engaging the DNMT3A2 molecule (Figure 
15.B) [95]. The WD-repeat protein 5 (WDR5) is a core component of SET1-family 
complexes that achieve transcriptional activation via methylation of histone H3 on Lys 5 
(Figure 15.C) [96]. The recombination activating gene (RAG) 2 contains a plant 
homeodomain (PHD) that recognizes histone H3 methylated at Lys 5 and influences 
V(D)J recombination (Figure 15.D) [97]. Histone demethylase LSD1 regulates 
transcription by demethylating Lys 5 of histone H3 (Figure 15.E) [98]. A substrate-like 
peptide was generated by a K5M mutation (marked in gray in Figure 15) because this 
mutation led to 30-fold increase in binding affinity thereby helping to stabilize the 
complex. Phosphorylation at Ser 11 of histone H3 enhances GCN5 histone 
acetyltransferase (HAT) mediated Lys 15 acetylation, promoting transcription (Figure 
15.F) [99]. The 14-3-3 isoforms present a class of proteins that mediate the effect of Ser 
11 phosphorylated histone H3 (Figure 15.G) [100]. The jumonji domain of JHDM3A 
(JMJD2A) catalyzes the demethylation of di- and tri-methylated Lys 10 and Lys 37 in 
histone H3 (Figure 15.H) [101]. DIM-5 is a histone H3 Lys 9 methyltransferase that is 
essential for DNA methylation (Figure 15.I) [102]. 
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Figure 15.J summarizes the results of disorder/order predictions, potential 
interacting regions and annotated post-translational modification (PTM) sites in UniProt 
in human histone H3. In general, H3 has a central structural region (residue 58-132) that 
matches to a Pfam family (histone: core histone H2A/H2B/H3/H4) and a long N-term 
disordered tail (around 38-48 residues in length). A similar disorder/order estimate was 
given by PONDR VSL2B. Within current 294 PDB entries related to human histone H3 
(27-Mar-12), 40 complexes were found to include H3 fragments (MoRFs) between 
residue 2 to 34. This N-terminal binding region was not recognized by both MoRF1 and 
MoRF2 predictors [45,103], but we claim the reasons may be because these two 
predictors were built specifically for helix MoRFs, not coil MoRFs like the ones in H3. 
Figure 15.A-I show the nine MoRFs found in the same region are all coil MoRFs. Part of 
the binding region can be predicted by ANCHOR [47] while the entire region can be 
found by MoRFpred [48] method. Based on the sequence annotations of UniProt 
database, most PTM sites of H3 are located in the N-terminus of H3, implying the 
functionally regulation sites may highly tie with MoRFs within disordered regions. 
Otherwise, it is very likely that there are 2 to 3 MoRFs tandem one by one in this case 
(e.g. 1-7; 8-14; 15-22). 
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A. JMJD2A   A R T K Q T A                   
B. DNMT3L   A R T K Q T A                   
      C. WDR5   A R T K Q T A R                  
    D. RAG2   A R T K Q T A R K                 
      E. LSD1   A R T M Q T A R K S T G G K A P          
Histone H3/1-136 1 M A R T K Q T A R K S T G G K A P R K Q L A T K A 25 
      F. HAT A1         A R K S T G G K A P R K Q L A     
      G. 14-3-3         A R K S T G G K            
      H. JHDM3A        T A R K S T G G             
      I. DIM-5         A R K S T G G             
    D.  RAG2 & H3                                  E.  LSD1 & H3                             F.  HAT A1 & H3                              
   A.  JMJD2A & H3                              B.  DNMT3L & H3                        C. WDR5 & H3  
      G. 14-3-3 & H3                               H. JHDM3A & H3                       I.  DIM-5 & H3                  
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Figure 15. Nine different binding partners of ι-MoRFs in the N-terminus of histone H3. 
Its partners include (A) Jumonji domain-containing protein 2A, (B) DNA-
methyltransferase 3-like, (C) WD-repeat protein 5, (D) VDJ recombination-activating 
protein 2, (E) lysine-specific demethylase 1, (F) Histone acetyltransferase (HAT A1), (G) 
14-3-3 protein zeta/delta, (H) Jmjc domain-containing histone demethylation protein 3A, 
and (I) Histone H3 methyltransferase DIM-5. (J) Schematic diagram of histone H3 
protein shows its predicted and validated disordered tails and a central folded domain. 
Structural data and various disordered binding site predictors reveal the potential binding 
regions of H3 are highly associated with posttranslationally modified sites. The residues 
in red in A-I are PTM sites in PDB, and the methionine in gray is residue that was 
mutated for the structural study. The annotated PTM sites on the entire H3 in J is from 
UniProt.  
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3.1.3. Alternative Splicing and Posttranslational Modifications in One-to-Many 
Binding 
Our 23 MoRF examples of one-to-many binding comprise a special set, 
containing partners with little sequence similarity that bind to MoRFs with identical 
sequences. This approach is distinct from the concept of structural compensation or 
coadaptation, for which mutations on one partner are linked to compensating mutations 
on the  partner [104]. It would certainly be possible to lift the requirement of MoRF 
sequence identity to thereby study coadaptation in complexes involving disordered 
proteins. Indeed, we have work in progress along these lines for a few specific examples 
to determine whether coadaptation between two structured proteins is different from 
coadaptation between structured proteins and MoRFs. 
There have been several previous bioinformatics investigations of large numbers 
of IDP-involving protein-protein interactions at a high level, without paying attention to 
the structural details [45,103,105,106]. Instead, our approach here is to investigate fewer 
MoRF examples, but in greater in detail in order to develop a deeper understanding of 
how intrinsically disordered proteins can alter their conformations so as to be able to bind 
to structurally distinct partners. Our observations demonstrated that, in general, 
conformation flexibility allows for both subtle and complex structural variation, thereby 
enabling the same sequence to transform onto the diverse and distinctively shaped 
binding sites provided by their partners.  
The MoRFs collected and grouped into one cluster herein are typically gathered 
from different organisms. As suggested by others, through parallel or convergent 
57 
 
evolution, such MoRFs can exist as conserved functional motifs or regions among 
various species, such as human, mouse, yeast, E. coli, or even viruses [107].   
As pointed out previously [105], such short linear motifs are amenable to 
convergent evolution due to the limited number of mutations that are necessary for the 
generation of a useful motif. In fact, motifs are commonly used as adding new functional 
modules within a proteome, especially in higher eukaryotes [108]. These short functional 
linear motifs are hypothesized to have higher levels of conservation, to frequently evolve 
convergently, to preferentially occur in disordered regions and to often form a specific 
secondary structure when bound to interaction partners [107]. This observation fits in 
with the conception that alternative inclusion of exons in different tissues provides 
functional diversity of proteins. In fact, embedded conserved binding motifs and post 
translational modification sites are both rich in tissue-dependent protein segments [109]. 
The tissue-dependent spliced regions have higher percentage of protein disorder that 
likely form conserved interaction surface and participate significantly more protein 
interactions [110].  
Among the 23 MoRFs in our dataset, three MoRFs (TRAP220, Bim and amyloid 
A4 protein) were annotated in UniProt to be located in alternatively spliced regions. 
Alternative splicing has the potential to add or delete an entire MoRF region. In addition, 
MoRF-related functions could be modulated by alternative splicing by changing the 
expression patterns, localization and regulation. These complex mechanisms could lead 
to broad functional and regulatory diversity. For example, pro-apoptosis protein Bim has 
17 isoforms. Its predominant three isoforms, BimEL, BimL and BimS, all have the 
MoRF region (BH3 ligand) “DMRPEIWIAQELRRIGDEFNAYYAR”, which is 
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responsible for binding selectivity for their pro-survival protein binding targets and 
starting Bcl-2 regulated apoptosis. Those Bim isoforms lacking the BH3 ligand, e.g. 
Bimβ1-7, also lack pro-apoptotic activities.  
Two additional MoRFs were reported to have alternative splicing events based on 
studies of the tissue-specific splicing exon data set [109]. A MoRF region from nuclear 
receptor corepressor 2 is specifically expressed in only 1 of 14 tissue types.  As was 
pointed out [109], the tissue-specific alternative splicing that leads to presence and 
absence of binding sites in disordered protein regions leads to the “rewiring” of protein-
protein interaction (PPI) networks, and may therefore contribute fundamentally to tissue 
development. It would be very interesting to develop models for the alterations in PPI 
networks in different tissues that arise from alternative splicing, but unfortunately the 
partners for the tissue-specific MoRFs are simply not known.   
In a previous study, we found that alternatively spliced regions of RNA code for 
protein disorder much more often than for regions of structure, and we showed that such 
alternative splicing could lead to inclusion or exclusion of binding sites within the 
disordered regions [9]. Interestingly, of the human MoRFs studied here, 50% (4 of 8) are 
in exon regions that have been identified as included or excluded by alternative splicing.  
The discussion in the previous paragraph suggests that a concerted effort should be made 
to identify additional MoRFs that map to tissue-specific alternatively spliced regions and 
to identify their partners as well.  
In our previous study of the carboxy terminal tail of p53 bound to 4 different 
partners, we noticed that two of the complexes were distinguished by having PTMs, 
namely lysine acetylations for both examples.  Furthermore, the acetate groups both 
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became buried in the interfaces between the two MoRFs and their respective partners 
[46].  In this study we discovered that differences in PTMs occur commonly when 
MoRFs bind to alternative partners.  Furthermore, this use of modified side chains to bind 
to one of two partners is most common when the two partners are structurally distinct. 
Indeed in this study, of 13 MoRFs containing PTMs, 11 involve MoRFs that bind to 
differently folded partners, thus providing additional observations in support of this 
concept. Finally, the chemical group added via the modification is typically found buried 
or partially buried in the interface between the MoRF and its partner, which strongly 
suggests that PTM provides an important part of the signal for the MoRF to bind to an 
alternative partner.   
Phosphorylation occurs much more often in intrinsically disordered as compared 
to structured regions of proteins [111,112].  Recently, several other types of PTM have 
been shown to prefer disorder over structure [113]. The results presented herein suggest 
that such a modification can be used to change the partner preference of a given MoRF, 
thus leading to switching the connections of a protein-protein interaction network.   
3.2. Many-to-One Binding 
A total of 4368 binary protein complexes were collected from the Protein Data 
Bank for which two or more peptides of different amino acid sequences were bound to 
the same (100% sequence identical) globular protein partner, a type of interaction that we 
call many-to-one binding. These peptides, which are embedded within putative 
intrinsically disordered protein (IDP) regions and which we call molecular recognition 
features (MoRFs), were restricted to be of length 5 to 25 residues. Two distinct binding 
profiles were identified in the collected many-to-one binding dataset: independent and 
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overlapping (varying from similar to intersecting). Within a subset of 139 selected 
protein-protein interactions, 72 or 51.8% of MoRF binding sites are similar within their 
own cluster. For this similar binding profile, the distinct MoRFs interact with almost 
identical binding sites on the same partner. Next, 33 or 23.7% of the MoRF binding sites 
are independent. For this independent binding profile, the MoRFs within the same cluster 
interact with completely different parts of the same binding partner. Finally, 34 or 24.5% 
of the MoRF binding sites intersect without being highly similar. For this intersecting 
binding profile, the binding sites contain both common and unique interaction residues. 
Relatively higher sequence conservation is noted for those partner interfaces with similar 
binding residues.  Further analysis of the sequence and structural changes within these 
three groups indicate how an IDP’s flexibility allows different segments to adjust to 
similar, independent, and intersecting binding pockets.   
Table 6 summarized all the procedures to collect our many-to-one binding dataset. 
First of all, 8084 short binding MoRFs having 5 to 25 residues were found in the PDB as 
of June 19, 2012. Within the initial MoRF set, 7064 of them have interactions likely to be 
of biological significance as estimated by the criterion of a buried surface area larger than 
400 Å2. There are 6835 of these interaction complexes having folded binding partners 
whose sequence lengths are more than 40 residues. In order to identify peptides bound to 
the same partners, partner sequences were mapped back to their parent sequences. Here, 
4612 partner sequences exhibited an exact match in Universal Protein Resource (UniProt) 
sequence database. 4368 partners were observed to overlap with at least one other 
protein, thereby leading to 514 distinct partner sets. After removing identical sequences 
with just one partner, 384 clusters with 2081 MoRFs were assembled. In other words, 
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each globular domain on average associates with 2081/384 = 5.4 different binding 
sequences.   
 
Table 6. Description of many-to-one MoRF dataset 
Data set MoRFs/ 
Partners 
Clusters MoRFs 
per cluster 
Initial MoRF dataset (5-25)
 a
 8084   
MoRF dataset with biological interaction (>400Å
2
)
 b
 7064   
Partner dataset with sequence length (>40)
c
 6835   
Partner dataset mapped to UniProt sequence database
 
 4612   
Partner dataset with overlapped region in mapping
 d
 4368 514 8.50 
Partner dataset without 100% sequence identity in MoRF 2081 384 5.42 
a
MoRFs with 5 to 25 residues are the focus of this study. 
b
400 Å
2 
cutoff was set to filter out the spurious interactions caused by crystal contacts. 
c
Binding partners of MoRF are supposed to be globular proteins having more than 40 
residues to fold into a certain conformation.  
d
Partners having one or more overlapping residues with each other. 
 
 
3.2.1. Peptide-Protein Interactions and Protein-Protein Interactions 
Rather than attempting a detailed analysis of 2081 complexes grouped into 384 
clusters, we elected to study a smaller number in greater detail, thereby making one-by-
one visual inspection of each complex much more practical.  In the end, we turned our 
attention to 160 globular proteins bound to 909 MoRFs, giving an average of 909/160 = 
5.7 sequences bound to each globular domain.  This group was used to characterize 
binding profiles. Furthermore, 21 peptide-protein interactions were set apart as a special 
subset since these interactions occur only after the MoRFs are enzymatically chopped 
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from their parent proteins. These MoRF partners are all immune-related and the MoRFs 
themselves have less sequence conservation with each other. The 21 immune-related PPIs 
and the remaining 139 PPI clusters were collected and inspected leading to their inclusion 
in Table 7. The 384 clusters of Table 6, the 21 immune-related clusters, and the 
remaining 139 clusters are compared with respect to their partner-number distributions in 
Figures 16 and 17.   
 
Table 7. Description of 2012 and 2008 MoRF datasets. 21 immune-related PPIs and 139 
nonimmune-related PPIs.  
 2012_dataset 2008_dataset 2008_immune 2008_nonimmune 
100% Quartile 
(max) 85 48 48 20 
75% Quartile 5 6 19 6 
50% Quartile 
(median) 3 3 4 3 
25% Quartile 2 2 2 2 
0% Quartile 
(min) 2 2 2 2 
average 5.42±7.86 5.68±6.79 13.05±14.64 4.57±3.55 
sum 2081 909 274 635 
count 384 160 21 139 
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Figure 16. The boxplot of 4 different datasets: MoRF_2012, MoRF_2008, 
MoRF_2008_immune, MoRF_2008_nonimmune. 
 
 
 
 
 
Figure 17. X-axis implies the counts of MoRFs within a cluster. Y-axis implies the 
counts of each cluster. The diagrams illustrated the data variation in different datasets as 
below: 
(A) MoRF dataset collected in 2012 
(B) MoRF dataset collected in 2008 
(C) Peptide-Protein interactions in 2008 dataset 
(D) Protein-Protein interactions in 2008 dataset 
  
A 
C D 
B 
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3.2.2. Binding Profiles: Independent and Overlapping (Similar vs. Intersecting) 
Using one-by-one visual inspection of the 139 protein-protein interactions and 21 
peptide-protein interactions, two main binding profiles were observed to describe many-
to-one interactions (Figure 18). The MoRF binding pocket on the partner side may be 
located in separated parts of the same binding partner (independent binding pocket) or 
contain both common and distinct interacting residues (overlapping binding pocket). The 
volume overlap ratio can range from almost 0% (intersecting binding pocket) to 100% 
(similar binding pocket).   
Table 8 gives a summary of each interaction category and the sequence identities 
of binding MoRFs. INDEL MoRFs are a set of similar MoRFs with only amino acid 
insertion or deletion on the terminal side within one cluster. On the other hand, mutative 
MoRFs have at least one amino acid difference as compared to the other MoRFs in the 
same cluster. 
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Figure 18. Many-to-one binding can be classified into two main categories: (A) 
independent and (B) overlapping binding pockets as the overlapping extent of a MoRF 
pair can range between (B.1) intersecting (overlap ratio: 0%) and (B.2) similar (overlap 
ratio: 100%). 
B.1 Intersecting 
(Overlap ratio: 0%) 
B.2 Similar 
(Overlap ratio: 100%) 
A. Independent  
Variable  
B. Overlapping  
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Table 8. Peptide-protein interactions and protein-protein interactions in many-to-one 
MoRF dataset. 
Interaction Type Clusters Identity Overlap ratio 
Peptide-protein interactions
a
 21   
G1 Similar binding pockets with INDEL
b
 MoRFs  0   
G2 Similar binding pockets with mutative MoRFs  15 0.29 0.42-0.72 (0.50) 
G3 Intersecting binding pockets  2 0.20 0.18-0.32 (0.25) 
G4 Independent binding pockets  4 0.35 0.00-0.48 (0.16) 
Protein-protein interactions 139   
G5 Similar binding pockets with INDEL
b
 MoRFs  24 1.00 0.42-0.80 (0.62) 
G6 Similar binding pockets with mutative MoRFs  48 0.60 0.40-0.88 (0.54) 
G7 Intersecting binding pockets  34 0.52 0.14-0.38 (0.29) 
G8 Independent binding pockets  33 0.52 0.00-0.46 (0.17) 
a
Peptide-protein interactions include MHC, T-cell receptor and antibody related complexes. 
b
INDEL MoRFs have either insertions or deletions with all the other MoRFs in the same cluster. 
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Sequence identities of interacting partner binding residues and RMSD of aligned 
multiple complexes can’t make a good distinction for the three main binding profiles. In 
order to quantify the similarity between MoRF fragments attaching to the partners, 
molecule volume calculations of each pair of MoRF were estimated. By dividing the 
volume of combined MoRF pairs by the volume of separate MoRF pairs, we can get the 
volume ratio from 0.5 to 1. The volume ratio was normalized from 0 to 1 to measure the 
extent that MoRF pairs overlap, and we termed the value as overlap ratio.  1 indicates two 
MoRF fragments are fully overlapped and 0 indicates two MoRF fragments are 100% 
spatially separated. The cluster would be determined as an independent binding pocket 
directly if there is one MoRF pair’s overlap ratio is 1 within the cluster. 0.4 was used as a 
cut off for overlap ratio to define similar binging pockets and intersecting binding 
pockets. In summary, we obtained 15, 2, 4 and 72, 34, 33 for similar, intersecting and 
independent binding pockets in peptide-protein interactions and protein-protein 
interactions, respectively. The overlap ratio for independent binding has a wider range 
because there might be similar or intersecting binding within the same cluster. The TAZ1 
domain was not included in our many-to-one binding dataset since its binding peptides, 
HIF1α and CITED2, are both exceeding the upper bound length criteria of MoRFs.  
Figure 19.A-J illustrates the data distribution of the three main binding profiles. 
The X-axis is the overlap ratio and Y-axis is the MoRF counts. The results imply the 
binding profiles of those peptide-protein interactions (immune-related) are very different 
from the regular protein-protein interactions (nonimmune-related). Unfortunately, the 
current way we used to classify the three binding profiles still need to be improved a lot. 
We are looking for a better way to separate the three classes by other algorithms.  
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                                    Overall PPIs        INDEL MoRFs in protein-protein interactions 
 
          
      Peptide-protein interactions                                Protein-protein interactions 
 
 
   
 
Figure 19. Histograms of pairwise overlap ratio based on all atoms calculations in the 
following datasets: 
(A) 160 many-to-one binding examples in 2008 dataset  
(B) Similar binding profiles with INDEL MoRFs in protein-protein interactions 
(C) Similar binding profiles in peptide-protein interactions  
(D) Similar binding profiles in protein-protein interactions 
(E) Intersecting binding profiles in peptide-protein interactions  
(F) Intersecting binding profiles in protein-protein interactions 
(G) Independent binding profiles in peptide-protein interactions  
(H) Independent binding profiles in protein-protein interactions 
(I) All peptide-protein interactions (immune-related)   
(J) All protein-protein intersections 
B A 
C D 
E F 
G H 
I J 
Similar Similar 
Intersecting Intersecting 
 
Independent Independent 
Overall Overall 
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Figure 20. Histograms of pairwise overlap ratios based on all atoms (blue), backbone+C-
beta (green) or backbone (red) calculations. 
 
The overlap ratios were calculated in three different ways using various set of atoms, 
including all atoms (blue), backbone + C-beta (green) or only backbone (red). Two-sample 
Kolmogorov-Smirnov tests were performed to examine whether the overlap ratio values 
calculated by different approaches have the same distribution at 5% significance level. The 
results show side chain conformations have a significant effect on the overlap ratio 
calculations (Figure 20).  
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The null hypothesis that each pair of distributions is the same could be rejected with   
the following p-values for each comparison as shown below: 
1.  “all atoms” vs. “backbone + C-beta” => p-value: 1.4187e-68 
2.  “backbone + C-beta”  vs. “backbone “ => p-value: 0.0704 
3.  “all atoms” vs. “backbone” => p-value: 6.2259e-72 
 
3.2.3. Structurally Conserved MoRFs with Diverse Sequences 
The conformations of the binding MoRFs with the identical partner were 
examined by comparing their secondary structure assignments (Table 9). Although 
MoRF sequences in each set are different, their folded secondary structures are highly 
conserved. 71% sets have identical secondary structure assignment, indicating dissimilar 
MoRFs tend to pack into a specific conformation upon binding to one partner. Coils are 
the majority of secondary structures on MoRFs (100 examples). Otherwise, 9 examples 
contain 3 secondary structure types and 38 examples have 2 secondary structure types, 
implying structurally diverse MoRFs also exist in part of our sets. In the peptide-protein 
interaction subset, the conformations of the MoRFs tend to converge toward coils. Within 
general protein-protein interactions, MoRFs bound to intersecting binding sites have 
more diverse structures than those binding to the similar binding sites. The INDEL 
MoRFs have more similar conformations than the mutative MoRFs. MoRFs with 
independent binding sites have the widest range of secondary structure types.   
In addition, we performed a simple amino acid composition profile comparison by 
a web-based tool called composition profiler [114]. Figure 21 shows the comparison 
between our query datasets (e.g. MoRFs, iMoRFs) and reference datasets (e.g. PDB, 
DisProt).   
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Table 9. The combination of secondary structure types in the 160 partner sets. 
MoRF    
Secondary structure 
Clusters G2 G3 G4 G5 G6 G7 G8 
α + β + ι + Complex 0 0 0 0 0 0 0 0 
α + β + ι 1 0 0 0 0 0 1 0 
α + β + Complex 1 0 0 0 0 0 0 1 
α + ι + Complex 4 0 0 0 0 0 1 3 
β + ι + Complex 3 0 0 0 0 2 0 1 
α + β 1 0 0 0 0 0 0 1 
α + ι 15 0 0 0 0 7 4 4 
α + Complex 2 0 0 0 2 0 0 0 
β + ι 8 1 0 0 0 2 3 2 
β + Complex 0 0 0 0 0 0 0 0 
ι + Complex 12 0 0 0 3 4 1 4 
α 10 0 0 0 4 4 0 2 
β 3 0 0 0 2 1 0 0 
ι 100 14 2 4 13 28 24 15 
Complex 0 0 0 0 0 0 0 0 
G1 to G8 imply distinct groups in two different types of interactions in Table 8. 
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Figure 21. Amino acid composition comparisons between various datasets: (A) MoRFs – 
PDB, (B) iMoRFs – PDB, (C) MoRFs – DisProt, (D) iMoRFs – DisProt, (E) iMoRFs – 
MoRFs and (F) DisProt – PDB. iMoRF means immune-related MoRFs. Data and diagrams 
were generated by composition profiler (http://www.cprofiler.org/) [114]. 
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3.2.4. Selected Many-to-One Case Studies 
Several representative complexes with different binding profiles in peptide-
protein interactions and protein-protein interactions were selected to delineate the many-
to-one binding dataset.  
(1) Peptide-protein interaction (immune-related) (Figure 22) 
Figure 22.A depicts HLA class I histocompatibility antigen as a diverse MoRF set 
(with only 16% pairwise sequence identity between 39 MoRFs) but bind to a similar 
binding region. MHC molecules display a molecular segment called epitope for antigen 
presentation. IgG2A FAB fragment has an intersecting binding region interacting with 17 
MoRFs sharing 19% sequence identity (Figure 22.B). Germline antibody FAB heavy 
chain binds to 2 MoRFs sharing 12% sequence identity without any overlapping their 
binding region (Figure 22.C). 
(2) Protein-protein interactions (nonimmune-related) (Figure 23) 
Six different binding profiles of protein-protein interactions were shown in Figure 
23. Figure 23.A represents five INDEL MoRFs binding to a similarly overlapped binding 
site on WD repeat protein 5. 11 MoRFs with 42% sequence identity bind to a highly 
overlapped region of TNF receptor associated factor 3 in Figure 23.B. Ten distinct 
MoRFs (26% sequence identity) bind to an intersecting pocket on proteinase K having an 
intersecting binding pocket in Figure 23.C. An intersecting binding also appears in alpha-
bungarotoxin bound to 10 MoRFs with 56% sequence identity. Two different patterns of 
MoRFs bind to two regions of chymotrypsin independently. Two patterns of MoRFs bind 
to two parts of focal adhesion kinase 1 separately. 
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                            Similar                                            Intersecting    
      
                        Independent                  
 
 
Figure 22. Peptide-protein interactions with similar binding pockets in (A) HLA class I 
histocompatibility antigen, intersecting binding pockets in (B) IgG2A FAB fragment and 
independent binding pockets in (C) Germline antibody 36-65 FAB heavy chain.  
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C 
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                      Similar                                              Similar  
 
        Intersecting                                   Intersecting 
   
       Independent                         Independent  
 
 
Figure 23. Protein-protein interactions with similar binding sites in (A) WD repeat 
protein 5 (B) TNF receptor associated factor 3, intersecting binding sites in (C) 
Proteinase K (D) Alpha-bungarotoxin and independent binding sites in (E) Chymotrypsin 
(F) Focal adhesion kinase 1. 
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3.2.5. Examples of Retro-MoRF and PP1-like MoRF 
Retro-MoRF is a putative concept that a MoRF partner would also bind to the 
reversed sequence of an identified MoRF. The rationale behind the concept is that 
flexibility of protein disorder is sufficient to accommodate the altered geometry of a 
reverse sequence [115]. Since our many-to-one dataset collecting multiple disordered 
sequences binding to one common partner, we developed an algorithm and tried to search 
all the retro-MoRF cases in each cluster computationally. 
Three poly-proline protein fragments were found to bind to the same pocket of 
actin regulatory protein profilin with both N-to-C terminal and C-to-N terminal directions 
(Figure 24). Profilin was demonstrated to bind to proline-rich peptides in two distinct 
backbone orientations like SH3 domain by X-ray crystallography data [116]. A poly-
proline protein fragments usually fold into polyproline helix: either poly-pro I (PPI) or 
poly-pro II (PPII).  
PPI helix is a right-handed helix with a much denser packing due to the cis 
isomers of its peptide bonds. PPI is rarer than PPII conformation because the cis isomer is 
not energy preferred. The dihedral angles for both conformations are close but not 
identical. There is no hydrogen bond within PPI or PPII helix. PPII helix is a left-handed 
helix with three residues per turn. PPII helices can be bound to SH3 domains. In addition 
to PPI and PPII, there are other proline-rich binding domains like WW and EVH1. 
Type 1 protein phosphatase (PP1) is regulated by inhibitor-2 (I2) by forming a 
complex with three MoRF regions within disordered I2: residues 12-17, residues 44-56 
and residues 130-169. Another two examples were found in our MoRF dataset which use 
the similar mechanism.  FXDXF motif (residues 1460-1471) and WVXF motif (residues 
77 
 
1479-1490) from synaptojanin 1 bind to an appendage domain from adapter-related 
protein complex 2. Insulin B chain (residues 25-43) and insulin A chain (residues 90-109) 
bind to an insulin degrading enzyme (Figure 25). 
 
       
Figure 24. Poly-Proline containing Retro-MoRFs interact with the same binding pocket 
of Profilin. 
 
  
 
 
 
 
 
Figure 25. Different MoRFs from the same parent protein bind to a common partner. 
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Q: 1460-1471 
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3.3. Many-to-Many Binding 
Besides one-to-many and many-to-one binding, we also found 12 interesting 
examples coexisting in both mechanisms, termed as many-to-many binding here. In each 
example, a common MoRF region interacts with different structured partners (one-to-
many) which associate with diverse MoRF sequences simultaneously (many-to-one). 
Notice that all the structured partners of these 12 examples are belong to similarly folded 
partner category. Table 10 is a summarized list of the 12 many-to-many binding set we 
found. 
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Table 10. A summarized list of the 12 many-to-many binding examples. 
 MoRFs Num of 
SPs 
SPs Num of 
MoRFs 
1 NCOA1 2 Estrogen receptor beta 2 
Peroxisome proliferator-activated 
receptor gamma 
6 
2 BAK peptide 2 BCL-XL 2 
M11L protein 0 
3 NR 0B2-N-term 2 NR5A2 3 
Ancestral corticiod receptor 0 
4 NCOA1 & 2 5 Androgen receptor 13 
Estrogen receptor 0 
NR1I3 2 
NR1I2 0 
Bile acid receptor 0 
5 NR 0B2-C-term 2 Peroxisome proliferator-activated 
receptor gamma 
6 
Androgen receptor 13 
6 GRIM 2 Apoptosis 1 inhibitor  4 
Apoptosis 1 inhibitor 4 
7 TRAP220 3 Vitamin D3 receptor 0 
Retinoic acid receptor, beta 0 
Retinoic acid receptor RXR-alpha 10 
8 Latent membrane 
protein 1 
2 TNF receptor associated factor 3 6 
Tumor necrosis factor receptor 
associated protein 2 
11 
9 NCOR2 3 Peroxisome proliferator activated 
receptor 
4 
Estrogen-related receptor gamma 6 
Progesterone receptor 2 
10 Amyloid beta A4 2 Disabled homolog 1 2 
X11 0 
11 DNA repair protein 
RAD9 
2 Protein kinase SPK1 5 
Probable regulatory protein embR 2 
12 Nicotinic receptor  2 Alpha-bungarotoxin 10 
Long neurotoxin 0 
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CHAPTER 4 
SCOP Folds of MoRF partners 
 
4.1. Partner Folds Selection in Each MoRF Types 
The binding diversity of protein disorder is a stumbling stone for modeling these 
cryptic disorder-order interfaces [117]. A typical example of MoRF in c-terminus of p53 
can transform into helix, sheet or coil structures to adapt four different binding surfaces 
of partners with different folds. Strikingly, preliminary data from Dr. Sarah Bondos’s 
laboratory reveals that Ultrabithorax (Ubx) protein prefers to interact with specific folds 
(Ref coming soon, PLOS ONE). Ubx is a Hox transcription factor and known to have 
intrinsically disordered regions regulating multiple gene regulations. Ubx coordinate 
multiple cell functions by associating with dozens of molecules. Evidence has shown that 
22 of 29 Ubx binding partners can be assigned to only seven SCOP (Structural 
Classification of Proteins) folds, implying a possible hypothesis: partner topology may 
predetermine the molecular recognition between various partner bindings. These findings 
motivate us to computationally explore a large number of disorder-order interfaces by 
looking at the relationship between MoRF secondary structure type and structural 
topology of its potential binding partners. 
Table 11 shows the SCOP fold classification of binding partners in each MoRF 
type (helix, sheet, coil and complex). There are totally 3148 MoRFs with 3750 SPs in our 
2008 MoRF dataset. However, some partners’ SCOP classifications haven’t been 
assigned by SCOP database. Also, one partner may have multiple SCOP classifications 
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since there may be several different domains within one partner. Both issues increase the 
complexity of our hypothesis validation process.  
Table 12 lists the major SCOP folds of MoRF binding partners that have greater 
than 2% proportion in each MoRF type. A trend was shown here that β-MoRFs prefer 
binding to all beta proteins (>52.4%) and α-MoRFs prefer to associate with all alpha 
proteins (44.2%).  
 
Table 11. The SCOP fold classification of binding partners in each MoRF type.  
 SPs Partners in SCOP  Folds in 
SCOP 
Non-redundant 
Folds in SCOP 
Ratio 
No Yes 
Helix 470 197 273 319 58 319/58=5.5 
Sheet 139 47 92 105 23 105/23=4.6 
Coil 2992 1026 1966 2999 145 2999/145=20.7 
Complex 146 79 67 86 28 86/28=3.1 
N/A in 
DSSP  
3 0 3 3 1 3/1=3 
Total 3750 1349 2401 3512 172 3512/172=20.4 
 
 
Table 12. lists the major SCOP folds of MoRF binding partners that have greater than 
2% proportion in each MoRF type. 
 α-MoRF P (%) β-MoRF P (%) ι-MoRF P (%) Complex-
MoRF 
P (%) 
Major 
SCOP 
Folds 
of 
SPs 
a.123 32.6 b.47 14.3 b.1 27.8 b.1 11.6 
b.1 9.1 b.1 11.4 d.19 14.3 a.123 10.5 
a.39 8.5 b.2 10.5 b.50 4.6 b.47 9.3 
c.23 4.4 b.50 9.5 a.118 3.4 b.50 8.1 
c.37 3.4 a.39 7.6 d.93 2.8 b.36 7.0 
a.24 3.1 b.36 6.7 d.144 2.6 b.22 5.8 
b.121 3.1 e.1 6.7 a.74 2.1 b.55 5.8 
d.5 3.1 d.131 5.7 b.47 2.0 b.61 5.8 
  d.5 5.7   a.11 4.7 
  d.39 3.8   d.15 4.7 
  d.144 2.9   g.7 3.5 
      a.39 2.3 
      c.55 2.3 
      g.52 2.3 
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Table 13. Classification of MoRF binding partners based on 4 different levels in SCOP. 
 Class Fold Superfamily Family 
Helix 9 58 64 73 
Sheet 5 23 24 25 
Coil 9 145 179 222 
Complex 6 28 29 34 
 
 
 
 
 
 
  
Figure 26. Venn diagrams of SCOP classification of MoRF partners in (A) class, (B) 
fold, (C) superfamily and (D) family levels for each MoRF type. 
  
A. Class B. Fold 
C. Superfamily  D. Family 
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Table 13 summarizes the statistics of SCOP classification of MoRF binding 
partners in class, fold, superfamily and family levels.  The same results were visualized 
and represented in another way showing in the Venn diagrams in Figure 26. Some more 
detailed information is listed in Table 14 (in SCOP class and fold level).  
 
 
Table 14.  Statistics of SCOP classification in (A) class and (B) fold levels of MoRF 
binding partners for each MoRF subgroup. 
 
 A. Class B. Fold 
Subgroup Count Member Count Member 
h 1 k 18 a.1,a.12,a.2,a.7,a.70,a.91,b.84,b.93,c.120,c.49,
d.104,d.129,f.1,f.23,f.32,h.4,i.22,k.21 
s 0  2 e.1,g.54 
c 0  89 a.102,a.129,a.133,a.144,a.146,a.158,a.20,a.20
2,a.22,a.23,a.246,a.29,a.35,a.48,a.58,a.60,a.74
,a.8,a.98,b.103,b.119,b.130,b.136,b.18,b.26,b.
3,b.57,b.62,b.68,b.70,b.72,b.82,b.85,b.86,b.9,
c.1,c.104,c.111,c.14,c.15,c.17,c.2,c.34,c.45,c.
47,c.52,c.56,c.57,c.66,c.69,c.7,c.72,c.8,c.93,c.
94,d.108,d.126,d.135,d.136,d.142,d.159,d.165
,d.166,d.169,d.17,d.195,d.198,d.20,d.200,d.22
3,d.33,d.54,d.56,d.58,d.88,d.9,d.95,e.28,e.3,e.
45,e.8,f.4,g.16,g.17,g.27,g.3,g.44,h.1,i.6 
com 0  6 a.223,b.108,b.81,b.91,d.231,g.1 
h+s 0  1 d.5 
h+c 2 f,i 25 a.118,a.24,a.28,a.4,a.59,a.71,b.121,b.29,b.34,
b.40,b.42,b.69,c.23,c.31,c.51,c.62,d.105,d.109
,d.110,d.185,d.42,d.86,d.92,g.14,g.41 
h+com 0  0  
s+c 1 e 6 b.4,b.76,d.19,d.3,d.39,d.93 
s+com 0  0  
c+com 0  7 b.22,b.6,b.8,c.41,c.55,d.26,h.3 
h+s+c 0  3 a.42,b.2,d.131 
h+s+com 0  0  
h+c+com 2 c,h 4 a.123,a.66,b.61,c.37 
s+c+com 0  4 b.36,b.50,g.52,g.7 
h+s+c+com 4 a,b,d,g 7 a.11,a.39,b.1,b.47,b.55,d.144,d.15 
 10  172  
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CHAPTER 5 
Conclusion 
 
When the idea of hub-based “scale free” protein-protein interaction networks was 
first proposed [10], a News and Views article pointed out that such multiple interactions 
were unlike what had been studied up to that time and that an understanding of these 
multiple interactions would likely require the discovery of new concepts [12]. Our 
laboratory immediately tried to suggest that the new principle was likely the use of 
disordered proteins by means of coupled binding and folding, which had been previously 
suggested for protein-DNA interactions [118] as well as for one protein binding to 
several partners [104], but publication of these ideas for hub proteins was delayed 
somewhat [51]. By now there is strong evidence that, at least for many if not all hub-
partner interactions, disorder plays an important role in enabling one protein to bind to 
multiple partners [17-19,51].  
As we have shown here, one MoRF can bind to multiple partners and, through 
these sets of interactions, a small region of one protein can play a role in multiple 
signaling events, thereby affecting several different cellular functions. Limitations on the 
availability of multiple interactions in PDB led to a small dataset, which, nevertheless, 
showed consistent results in terms of residue conservation in the binding partners. By 
restricting sequence identity of binding partners to 25% we were hoping to find MoRFs 
binding to structurally diverse partners, but it turned out that in most cases the partner’s 
folds were very much conserved, despite the sequence differences. Aromatic residue side 
chain re-orientation was shown to contribute significantly on binding interfaces in two 
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and three interactions when the backbone conformation remained constant. Overall, these 
results paint a more detailed picture of multiple interactions than what has been available 
to date, and support the notion of intrinsic disorder or structural adaptability as an 
important factor in the development of non-random protein interaction networks 
characterized by multiple binding partners. 
Despite the biological and structure-function importance of these disorder-based 
multiple protein interactions, there have been surprisingly few studies indicating in detail 
how such multiple interactions are brought about. Investigating more examples in detail 
is needed to provide a clearer and more general picture of how the one MoRF sequence 
can bind to two or more different partners. 
To broaden our understanding, it makes sense to study different collections of 
single proteins binding to multiple partners and to study multiple proteins binding to the 
same partner.  Previously we investigated one segment binding to completely unrelated 
partners (e.g., one-to-many signaling) and a collection of unrelated disordered partners 
binding to a single binding site on one structured protein (e.g. many-to-one signaling) 
[46].  Rather than focusing on individual examples as before [46], here we studied a 
collection of MoRFs involved in binding to more than one partner.   
A distinctive feature of this study is the partners to a given MoRF had a sequence 
identity less than 25% yet displayed the same overall fold. In general, sequence variations 
in one partner are frequently linked to sequence variations on the other partner, indicating 
structural compensation or coadaptation across the binding interface [104]. However, the 
interacting protein pairs we collected here are a special set in that only the partners show 
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amino acid substitutions in their sequences, whereas the MoRFs’ sequences are 
unchanged.  
The indispensability of hub proteins is apparent, as they appear to evolve more 
slowly and are more likely to be vital for survival [10]. MoRF-protein interactions likely 
have the combination of high specificity coupled with low affinity [45]. The latter 
property may facilitate the discovery of small drug molecules that block the interactions. 
This study and others like it have the potential for a new strategy for drug discovery, 
namely to search for molecules that selectively block certain protein-proteins interactions 
involving a given protein but not others, by taking advantage of different conformations 
in the different interactions. This would allow the development of drugs that target 
specific pathways or even particular pathways in particular tissue types. 
Observations have been made that the residues in enzyme active sites tend to 
evolve more slowly than other parts of the same proteins [80]. We wondered whether the 
same trend would also be found in the binding sites of the structured partners. By 
analyzing the 11 sets of interactions that we collected, we found that, like the active-site 
residues of enzymes, the binding residues of the structured partners exhibited a higher 
conservation as compared to the non-binding residues.  
A recent study showed that protein-protein interactions in which a disordered 
region binds to a structured partner often involves interactions between two aromatic 
groups, for which the aromatic residues are frequently not stacked but rather oriented in 
such a way that a hydrogen of one aromatic ring points towards the centers of the 
conjugated electron rings of the other [119].   In agreement with this study, many of the 
protein-protein interactions investigated herein do indeed involve interacting aromatic 
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residues, but specific examples without such aromatic-aromatic interactions were also 
found.    
Interactions between globular proteins and MoRFs often contain disordered 
residues as part of the MoRFs [38]. Others have shown that, even though such local 
regions remain unstructured, they can still affect the overall binding affinity. Such “fuzzy 
complexes” thus bind to their partners without undergoing complete conversion to 
structure with the regions that remain disordered still contributing to the energetics of the 
interaction [120]. From what we have shown here, a search for fuzzy complexes involved 
in one-to-many and many-to-one signaling could shed new light on these novel and 
interesting protein-protein “flexible nets”.  
Molecular recognition features (MoRFs) are intrinsically disordered protein 
regions that bind to partners via disorder-to-order transitions.  In one-to-many binding, a 
single MoRF binds to two or more different partners individually. MoRF-based one-to-
many protein-protein interaction examples were collected from the Protein Data Bank 
(PDB), yielding 23 MoRFs bound to 2 to 9 partners, with all pairs of same-MoRF 
partners having less than 25% sequence identity. Of these, 8 MoRFs were bound to 2 to 9 
partners having completely different folds, while 15 MoRFs were bound to 2 to 5 
partners having the same folds but with low sequence identities. For both types of partner 
variation, backbone and side chain torsion angle rotations were used to bring about the 
conformational changes needed to enable close fits between a single MoRF and distinct 
partners.  Alternative splicing events (ASEs) and posttranslational modifications (PTMs) 
were also found to contribute to distinct partner binding. Since ASEs and PTMs both 
commonly occur in disordered regions, and since both ASEs and PTMs are often tissue-
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specific, these data suggest that MoRFs, ASEs, and PTMs may collaborate to alter 
protein-protein interaction networks in different cell types. These data enlarge the set of 
carefully studied MoRFs that use inherent flexibility and that also use ASE-based and/or 
PTM-based surface modifications to enable the same disordered segment to selectively 
associate with two or more partners. The small number of residues involved in MoRFs 
and in their modifications by ASEs or PTMs may simplify the evolvability of signaling 
network diversity. 
The binding sites on the structured partners may also bind additional disordered 
sequences that have amino acid substitutions (e.g. many-to-one signaling). If such 
complexes exist, it would be interesting to determine whether the amino acid changes in 
the MoRFs compensate for the already observed amino acid changes in the structured 
binding partners.  We have a collection of many-to-one examples, so we can search this 
set of interactions to determine if any of the structured proteins in the many-to-one 
collection match any of the structured partners discussed herein. Such a finding would 
not only provide information about possible mutation compensation across protein-
protein interaction interfaces involving disordered protein regions, but would also suggest 
new concepts with regard to the structural basis of protein-protein interaction networks.  
The independent and overlapping binding profiles we observed in the many-to-
one set gave us a novel way to look at the dynamics of structural binding sites with 
binding diversity like 14-3-3. Although it is a challenge for us to categorize those 
overlapping binding sites into subgroups (e.g. similar and intersecting) quantitatively, 
volume overlap ratio calculations seems to work best compared to methods such as 
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RMSD measure of MoRFs, sequence similarity of MoRFs and structure alignment score 
of the MoRF-domain complexes.  
There are still many other interesting ideas waiting for us to try and test on this 
valuable many-to-one binding dataset. For example, examining the structures of MoRF 
pairs with different overlap ratios is what we will do in the next step. We are curious to 
see the pairwise secondary structure profiles within different overlap ratio groups (e.g. 
similar and intersecting). Partner selection of MoRF characterized by diverse binding is 
another interesting subject to follow up. Although we have observed posttranslation 
modifications (PTMs) and alternatively spliced  events (ASE) with regard to the MoRFs 
in our one-to-many set and proposed that the three major players (MoRFs, PTMs and 
ASEs) contribute significantly to the highly complex protein interaction networks in 
eukaryote cells, establishing a more systematically computational approach is necessary 
to validate our hypothesis.             
Our results contribute to a better understanding of the role of disorder binding 
regions (MoRFs) that may serve as protein interaction hubs. Exploring the diverse 
binding partners of our collected MoRF sets and the corresponding complex 
conformations definitely give us a general Rosetta stone to interpret the underlying 
biological mechanisms and evolutional aptness. The importance and indispensability of 
hub proteins is apparent as they appear to evolve more slowly and are more likely to be 
vital for survival. Given their importance, many human disease-associated proteins 
related to cancer, diabetes, autoimmune disease, neurodegenerative disease and 
cardiovascular disease are found to have predicted disordered binding regions (MoRFs) 
as we expect [121]. These MoRFs associate with other structured partners and considered 
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as promising druggable interactions because of their high specificity and low affinity for 
binding. Since intrinsic protein disorder have high tendency to participate directly in 
large numbers of pairwise protein-protein interactions, these promiscuous protein 
interactions usually are toxic when overexpressed. They are dosage sensitivity. The fact 
is contrast to knockout or knockdown model, indicating there is something special about 
the excess participation specifically in pairwise interactions [122].  
Binding with relatively low affinity is an advantageous attribute for transient, 
conditional and tunable interactions which is needed for many regulatory events. 
Therefore, this study will help pave the way for the development of novel pathways by 
designing intervening disordered peptides or small molecule having binding potential for 
particular partners but with tighter binding affinity.  
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